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Instructions for Authors
New molecular and pharmacological tools have made 
it possible for us to identify the intricate network that 
exists between the immune system and the brain, 
a network that allows the two systems to signal 
each other continuously and rapidly. Chemicals 
produced by immune cells signal the brain, and the 
brain in turn sends chemical signals to restrain the 
immune system. These same chemical signals also 
affect behavior and the response to stress. Disruption 
of this communication network in any way, whether 
inherited or through drugs, toxic substances or 
surgery, exacerbates the diseases that these systems 
guard against: infectious, inflammatory, autoimmune, 
and associated mood disorders. Many researchers 
studies have shown that stressful life events, from the 
death of a loved one to the loss of a job, are linked to 
an increase in certain health problems, particularly 
heart disease, diabetes, and hypertension. Many 
people assume that stress leads to cancer as well. 
Evidence for this, however, is not clear. However, the 
significance of mind-body interactions in medicine is 
now increasingly being recognised (1).
Disruption of an individual’s natural sleep-wake cycle 
has been determined to be a contributing factor in 
the development of organ disease. The effect of shift 
work on cancer, particularly breast cancer, has received 
increasing interest from the lay media since a panel 
of the International Agency for Research on Cancer 
declared in 2007 that “shift work that involves circadian 
disruption is probably carcinogenic to humans.” The 
majority of studies have dealt with shift work and 
risk of cardiovascular disease,in particular coronary 
heart disease, have given conflicting results possible 
because methodological problems are present in 
most studies in relation to selection bias, exposure 
classification, and the appropriateness of comparison 
groups. The study by Moy FM in this issue does not 
provide any evidence for a relationship between shift 
work and cardiovascular risk factors (2).
Cancer is the second commonest cause of death in 
Malaysia. A total of 21,773 cancer cases were diagnosed 
among Malaysians in Peninsular Malaysia in the year 
2006 and registered in the National Cancer Registry. 
It comprises of 9,974 males and 11,799 females. The 
Age standardised Incidence Rate (ASR) for all cancers 
in the year 2006 regardless of sex was 131.3 per 
100,000. and the five most common cancer among the 
population of Peninsular Malaysia in 2006 were breast, 
colorectal, lung, cervix and nasopharynx. A national 
cancer control programme on modifying risk factors 
for developing cancer (prevention), early detection, 
treatment and rehabilitation of patients with cancer is 
important in reducing the morbidity and mortality 
from this disease.
Breast cancer is the commonest cancer in women in 
Malaysia. Lifestyle can reduce the risk of breast cancer. 
Breast feeding for a prolonged period can protect 
against breast cancer and should be encourages. 
However a study on the prevalence of breast 
feeding in Kedah showed that only 21% of mothers 
breast-feed exclusively for 4 months, and women of 
higher education are more likely to practise breast 
feeding as they understand the benefits of breast 
feeding (3).
Occupational hazard play a small role in the causation 
of cancer, especially in the rare cancers such as 
squamous cell carcinoma of the scrotum, which has 
been associated with paraffin and shale oil workers 
(4).
Cancer may sometimes present not as the primary 
tumour, but as a para-neoplastic syndrome such as 
the oncogenic osteomalacia, characterised by bone 
pain and muscle weakness, and these are caused 
by a tumour of mesenchymal origin that secrete 
phosphaturic substances (5).
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Cancer patients on chemotherapy experience 
psychological distress which is often under-diagnosed. 
This may be due to the side-effects of chemotherapy, 
and also the uncertainty of having a life-threatening 
disease. Hence it is important to recognize and treat 
distress early (6). Targeted therapy, which does not 
have the side-effects of chemotherapy, is being 
developed, and these drugs inhibit specific pathways 
involved in pathogenesis of cancer, and one such drug 
is temsirolimus, which is an mTOR inhibitor shown to 
have efficacy in renal cell carcinoma (7) 
Cancer survivorship issues and quality of life are 
becoming increasingly important as with better and 
more effective treatment, women with breast cancer are 
living longer. Because breast cancer occurs in relatively 
young women, with more than 50% of women in the 
premenopausal age group, women with breast cancer 
face a multitude of problems related to sexuality. 
Surgery is often mutilating, chemotherapy brings on 
premature menopause, and there is a deterioration 
in sexual functioning which can post medical and 
psychological problems (8).
A fear of recurrence persists even after several years 
after a cancer is diagnosed and treated. Prognosis in 
breast cancer is generally good; however recurrences 
can occur even after many years. Clinicopathological 
features can be used to predict the likelihood of a 
relapse, and the study by Rozita AM et al in UMMC 
showed that disease stage, nodal status and estrogen 
receptor status were significantly correlated with risk 
of relapse (9).
Finally, we must not forget that while prescribing drugs 
such as chemotherapy and targeted therapy may carry 
side-effects, even simple drugs like antibiotics, is also 
not without adverse effects, and antibiotics can lead 
to Stevens- Johnson syndrome, and judicious use 
of medication with patients education is important 
(10).
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ABSTRACT:
In the last three centuries, medicine has focused predominantly on the physical body as the source 
of disease, placing very little importance on the mind. However, the significance of mind-body 
interactions in medicine is now increasingly being recognised. True health must include both the 
physical body and the mind. This article traces our concepts of the relationship between mind 
and body since primitive times and explores its relevance to the maintenance of health. (JUMMEC 
2010; 13(1): 3-11)
KEYWORDS: mind-body interaction
Introduction
For centuries, scientific thinking had been based on 
the concept of the separation of body and mind. ‘Body’ 
refers to all matter and physical phenomena, including 
the human body. ‘Mind’ refers to the unseen, spiritual, 
psychological aspects of life, including reason, intellect, 
memory, attention, will and emotion. It is the aspect of 
a person that enables the person to be aware of the 
world, to think and to feel.
Rene Descartes, the seventeenth-century French 
philosopher and mathematician, drew a strict 
distinction between mind and body. Descartes’ mind-
body dualism became the foundation of Western 
thought for many years and contributed to the 
separation of theology and science, of materialism 
and spiritualism, of body and mind. It supported 
the distinction in medical science between physical 
phenomena or diseases and those of a mental or 
emotional nature. To Descartes, the human body was 
a machine reducible to elementary parts and systems. 
While the idea of mind-body separation still remains 
strong to this day, the distinction has begun to fade as 
science and medicine make new discoveries.
A historical overview of our understanding of 
mind-body interaction
In primitive society (10000BC), disease was thought to 
be primarily caused by spiritual powers and, therefore, 
could be treated only by spiritual means. The evil 
spirit entering the human being had to be liberated 
through exorcism and similar means. The emphasis 
was almost exclusively on the spirit and there was 
very little consideration of the physical body. In some 
societies, even today, there is a dangerous lack of 
respect for medical science and an excessive reliance 
on superstition. 
In the ancient civilizations such as the Babylonian-
Assyrian Civilizations (2500-500BC), medicine was 
often dominated by religion. Many Egyptian beliefs 
were based on myths and legends. However, there 
is evidence that in ancient Egypt, interest in human 
anatomy started to increase and there existed people 
who were referred to as physicians. 
With time, a more holistic approach was adopted. 
There was more interest in the scientific study of the 
physiology of the human body, in addition to the 
psychological and spiritual aspects of life. The ancient 
Greek physician, Hippocrates, thought to have lived 
around 460BC to 370BC and often referred to as the 
‘father of medicine’, wrote in his treatise, entitled 
Tradition in Medicine, that “no one can understand 
the science of medicine unless he knows what man 
is” (1), emphasizing that in order to cure the human 
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body, it is necessary to have a knowledge of the 
whole of things. Over the following hundreds of 
years (100BC-AD400), various theories of the causation 
of disease were put forth, such as Galen’s humoral 
theory that disease was caused by disturbance in 
the body fluids. This continued until the Middle and 
Dark Ages (around AD500-1450) when mysticism 
again dominated medicine. Sinning was thought to 
be the cause of mental and somatic illnesses.
During the Renaissance period (1500-1700), there was 
revival of interest in the natural sciences and their 
application to medicine as well as advances in 
anatomy, autopsy, microscopy and others. Around 
the 17th century, Descartes’ concept of the ‘dualism’ 
or separation of the mind and body started to exert 
a strong influence on Western thought. In the 19th 
century, modern laboratory-based medicine, such as 
that practiced by Pasteur and Virchow, opened up a 
new era in medicine. From that time onwards, doctors 
began to feel that disease had its origin in disorders 
of the cell. The development of better microscopes 
enabled more details to be examined. Medicial 
practitioners became convinced that all disease must 
be associated with some kind of structural or functional 
cell change. Our understanding of the workings of 
the human body as well as of pathological processes 
progressed by leaps and bounds. 
As time went on, however, the inter-relationship of 
the mind and the body was rejected as unscientific 
and matters related to the mind were relegated only 
to the realm of religion and philosophy. In the last 
three centuries of human existence, medicine has 
focused predominantly on the physical body as the 
source of disease, placing little importance on the 
mind. We have swung completely in the opposite 
direction from the days of our forefathers in primitive 
society where illness was thought to be entirely caused 
by spiritual powers. Although it has brought about 
many benefits, progress in the scientific understanding 
and treatment of disease is, unfortunately, in many 
instances also accompanied by a situation where the 
disease is treated, but not the whole patient. With 
its analytical and specialising approach, western 
medical science, though possessing great knowledge 
about pathological conditions, often regards illness 
and the diseased organ as separate from the human 
beings who are inflicted by the illness. This is an 
unfortunate consequence of the concept that mind 
and body are separate entities.
Professor Felix Unger, head of Cardiac Surgery at 
Salzburg State Hospital and President of the European 
Academy of Sciences and Arts, comments on the 
state of medical science today as follows: “Its strong 
inclination towards the natural sciences has caused 
medicine unintentionally to regard patients as peculiar 
cases describable in natural-scientific terms” (2).
Psychological and physical illness — is there a 
real division?
A large proportion of the training of doctors today is 
centred on the scientific diagnosis and treatment of 
diseases of the body. In doing so, we often categorise 
and compartmentalise. While this is important to 
enable us to make sense of the large and ever-
increasing body of medical knowledge, it has also led 
us, whether consciously or not, to separate the so-
called ‘mind’ problems and the ‘body’ problems in our 
clinical practice, ignoring their inter-relationship. 
It is now a common tendency to classify illnesses into 
those that we think have a physical or organic cause 
and those, which we consider to be psychological 
or psychosomatic or non-organic in origin. This is 
undoubtedly convenient for the busy clinician but there 
is increasing awareness that such clear-cut division 
of diseases into ‘physical’ (body) and ‘psychological’ 
(mind) categories is an oversimplification and often 
wrong. We are beginning to recognise that all diseases, 
even genetic diseases and congenital malformations, 
have both physical and psychological elements that 
we cannot ignore. The mind and the body may appear 
separate, but they are, in fact, unified. 
When patients discover they have serious illnesses, the 
accompanying shock has major effects on their mental 
and emotional states. Illness affects how one feels 
in many ways, often causing one to plunge into the 
depths of depression. In the case of children, their self-
image and development can also be affected. In many 
instances, the impact upon their young minds can have 
lasting consequences. 
The mind can also affect the body. It is well recognised 
that symptoms of ‘physical’ diseases such as peptic 
ulcer disease can worsen in times of stress. Severe 
5emotional turmoil can precipitate a cardiac arrest. 
Great joy as well as deep sorrow lead one to shed 
tears. Expressions in the English language such as 
‘trembling with fear’, ‘the heart beating in excitement’ 
and ‘shaking with laughter’ show that even long ago, 
people have recognised the influence of emotions on 
the body. One’s emotional state is revealed in one’s 
physical appearance and attributes of the mind such 
as confidence is reflected in the quality of one’s voice.
Functional gastrointestinal symptoms in 
children 
There are a large number of children with severe 
physical complaints - such as headache, abdominal 
pain and vomiting - without any detectable physical 
cause. The pain experienced by these patients is real, 
and often, very severe and yet, conventional tests 
could not reveal any pathology. 
A survey of elementary school-children in Malaysia 
revealed that about ten percent of them suffered from 
the syndrome of recurrent abdominal pain, defined 
as at least three episodes of stomach-aches intense 
enough to interfere with their daily lives over a period 
of at least three months (3). Among Malaysian children 
with recurrent abdominal pain who were admitted to 
hospital, a significant proportion of over 95% were 
found not to have detectable abnormalities that 
could account for the symptom, whether on physical 
examination or investigation (4).
The presence of organic pathology does not necessarily 
imply that it is the cause of a patient’s symptoms. For 
example, the organism Helicobacter pylori was once 
proposed to be an important cause of childhood 
recurrent abdominal pain. However, analyses of various 
paediatric studies suggest that there is insufficient 
evidence to support this proposal (5). In a study on H. 
pylori sero-positivity, a relatively high prevalence of H. 
pylori (16.7%) was noted in asymptomatic Malaysian 
teenagers, indicating that the organism could be 
present without causing symptoms (6). Furthermore, 
the prevalence of H. pylori sero-positivity among 
asymptomatic Malaysian children was lowest in Malays 
(6.6%), intermediate in Chinese (10.4%) and highest in 
Indians (17.9%) (6). Interestingly, this was the opposite 
of the prevalence pattern of recurrent abdominal 
pain found in the same population where recurrent 
abdominal pain was most common in the Malays 
(11.9%), intermediate in the Chinese (9.3%) and least 
common in the Indians (8.2%) (7).
Current research shows that childhood recurrent 
abdominal pain is multi-factorial in origin with 
a major psycho-social component. For instance, 
a strong correlation has been found between 
stressful life-events and the occurrence of recurrent 
abdominal pain in both rural and urban school-
children aged between nine and fifteen years (8, 9, 10). 
The life-events included the loss of a family member 
through death, the change in occupation of a family 
member, hospitalisation of a family member, the 
child’s own hospitalisation, recent change of address, 
change in occupation of an immediate family member, 
failure in a major school examination and bullying at 
school. Stressful life-events was not only associated 
with increased complaints of physical symptoms, 
but was also linked to poor academic performance 
(11). What is worrying is that children with recurrent 
abdominal pain often miss school on account of their 
symptoms, with studies showing that at least a third of 
these children missed more than two weeks of school 
over a six-month period (7).
Another condition frequently seen is the syndrome of 
cyclical vomiting, which is a condition characterised 
by recurrent stereotypical bouts of vomiting with 
intervening periods of normal health and the absence 
of an organic cause. Many of these patients have some 
kind of psychosocial precipitating factor. 
The following case of a ten-year-old boy with recurrent 
vomiting illustrates the problem. He was the only 
child of well-educated parents. The child’s episodes 
of vomiting occurred several times a year and were 
often severe, resulting in electrolyte disturbances. 
Hospital investigations did not reveal any organic 
cause for the symptoms. There were no obvious 
precipitating factors at first. However, a more detailed 
history revealed that there was a feeling of guilt in the 
family originating in the grandfather and transmitted 
also to his father. The grandfather was a soldier who 
had killed during war and unresolved feelings of 
profound guilt led him to commit suicide a number of 
years ago. The family did not discuss this matter openly. 
However, it was a severe shock to the sensitive 
young boy and suppressing it all was likely to be 
an important cause of his symptoms. Once this 
possibility was recognised and the whole family was 
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encouraged to talk about it, the episodes of vomiting 
started to reduce significantly. 
The above studies and case report show that issues of 
the mind cannot be separated from those of the body. It 
is essential not to just look at the physical aspect alone, 
even though it may appear that the patient – whether 
adult or child - is only complaining of a physical 
symptom such as “abdominal pain” and “headache” 
or diagnosed with a so-called “physical disease” like 
“asthma” and “diabetes”. It is important to know what 
the patient and, indeed, the family are thinking about 
and feeling – otherwise the management of the patient 
is incomplete. A doctor needs to pay attention to more 
than a diseased organ, more even than the whole man 
– it is crucial that he considers the man in his world. 
An important obligation of adults today is to create the 
conditions in the family, the school and in society for 
children to grow up happily with healthy bodies and 
minds. Symptoms such as stomach-aches and vomiting 
can often be a child’s subconscious cry for help. 
Giving adequate time to the child and listening with 
concern to whatever he or she has to say is essential if 
we wish to understand the world of our children and 
help them. Parents and teachers who do not realize 
this point exacerbate the problem and end up putting 
further pressure on the child. This can lead to chronic 
illness. 
The body’s reaction to psychosocial stress and 
depression
One of the areas where mind-body interactions has 
been studied is the effects of mental conditions such 
as depression and stress on the body. ‘Stress’ can be 
described as a condition that affects people when 
the demands made on them exceed their capacity 
to meet those demands (12). A number of papers have 
shown that there is association between depression 
and stress on the one hand and diseases traditionally 
thought to be ‘physical’ or organic diseases on the 
other. 
Depression was found to coexist with Crohn disease 
more often than would be expected by chance (13, 14). 
It is unclear whether depression occurred as a result 
of the disease, or whether depression played a role in 
facilitating the expression of the inflammatory bowel 
disease. Depression has also been found to increase 
mortality and morbidity in patients with heart failure. 
Such adverse associations persist after adjustment for 
conventional prognostic risk factors (15).
It is not entirely clear what the mechanisms are 
that account for the observed association between 
various diseases and depression or stress. In recent 
years, there have been various studies that attempt 
to look at possible mechanisms, although, we still do 
not have a completely satisfactory explanation. For 
instance, depression has been found to be associated 
with inflammation as evidenced by the finding of 
increased levels of C-reactive protein (16). Increased 
TNF-alpha levels and coagulation factors have also 
been shown to be present in depression (17, 18). 
Animal studies show that mice subjected to maternal 
deprivation develop a behavioural pattern reminiscent 
of depression and are more susceptible to inflammation 
(19). 
It has also been proposed that another possible 
mechanism linking depression with disorders such as 
cardiac pathology is autonomic imbalance. Some of the 
abnormalities that have been found include impaired 
parasympathomimetic functions and a dominant 
sympathetic drive (20, 21).
Whatever the mechanisms may be, mental or 
psychological stress has been linked to a variety of other 
conditions such as skin disorders, allergies, asthma 
and even malignancy. Depression and hopelessness 
seem to reduce the body’s resistance, making one 
vulnerable to various illnesses. Further studies are 
needed to obtain more evidence but what is available, 
so far, seems to support the concept that mind and 
body are inseparable. 
The effect of a positive mind-set on the body
While there have been some studies on the negative 
effects of stress and depression on the body, even less 
is known about the effect of a positive mind-set. It 
seems reasonable, however, to propose that a positive 
mind-set should also have positive effects on the body. 
What are the effects of positive psychological events 
on the body? We are still in the early stages of 
understanding and there are not many studies that 
test and document this possibility. There are, however, 
many anecdotal reports from reputable sources and it 
would be unwise to disregard them. 
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Using again the example of Crohn disease quoted 
earlier, my own unpublished experience suggests 
that there are some patients with a severe form 
of the disease who have better outcome than others 
with less severe physical disease but who are anxious, 
tense and withdrawn. These patients are usually 
positive individuals, who do not let their illness limit 
their functioning, participating in a wide range of 
academic and extracurricular activities. 
The late Dr. Norman Cousins (1915–1990), formerly an 
adjunct professor at the School of Medicine, University 
of California, Los Angeles (UCLA), wrote in an article 
published in 1976 in the New England Journal of 
Medicine as follows:
“The will to live is not a theoretical abstraction but a 
physiologic reality with therapeutic characteristics…I 
have learned never to underestimate the capacity 
of the human mind and body to regenerate – even 
when the prospects seem most wretched. The life-
force may be the least understood force on earth….
Human beings tend to live too far within self-imposed 
limits. It is possible that these limits will recede when 
we respect more fully the natural drive of the human 
mind and body toward perfectibility and regeneration. 
Protecting and cherishing that natural drive may well 
represent the finest exercise of human freedom” (22).
What was it that led Dr. Cousins to make such a 
comment? In the 1920s, when Dr Cousins himself 
was diagnosed with tuberculosis, he was sent away 
to a sanatorium where he noticed that although two 
patients might have similar medical conditions, the 
one who was hopeful and optimistic was far more likely 
to actually recover. Years later, he himself survived a 
life-threatening connective-tissue disease at the age 
of 50 and recovered from cardiac infarction at the 
age of 65. While cooperating fully with his physicians, 
Dr Cousins also realised that a crucial factor in his 
recovery was his own powerful determination to beat 
his illness. He, subsequently, became convinced that 
a positive determination to overcome illness could 
actually stimulate our organs and even individual 
cells towards health.
Exactly one hundred years ago, in 1910, Dr. William 
Osler, Regius Professor of Medicine at Oxford University 
made a similar observation in the British Medical 
Journal. 
“Nothing in life is more wonderful than faith - the one 
great moving force which we can neither weigh in the 
balance nor test in the crucible. Intangible as the ether, 
ineluctable as gravitation, the radium of the moral and 
mental spheres, mysterious, indefinable, known only 
by its effects, faith pours out an unfailing stream of 
energy…” (23).
The importance of giving patients the courage 
not to be defeated by their illness 
What is the practical clinical implication of knowing 
that there is close interaction between mind and body? 
Based on his experience, Dr. Cousins stated, as follows: 
“One of the doctor’s biggest jobs is to encourage to the 
fullest the patient’s will to live and to mobilize all the 
natural resources of body and mind to combat disease” 
(22, 24, 25).
S is a patient who is now in her twenties. She had 
biliary atresia and had a Kasai operation. Although the 
operation managed to overcome biliary obstruction 
and re-establish bile flow, her liver had already 
been damaged before surgery and she needed 
constant follow-up and surveillance. About five years 
previously, her mother, who had been her pillar of 
support, died from breast cancer. Her bereavement, 
together with her own chronic illness, caused her to 
fall into the depths of depression and she lost the will 
to live. However, with constant encouragement from 
her father as well as the medical and nursing staff, 
she managed not only to live on but also developed 
the courage to pursue tertiary education. 
When one of her doctors saw her, she told him with 
pride that she had completed her university thesis 
on the activities of young women during the Second 
World War. It was an academic thesis but at the 
same time, it was full of feelings of sympathy for the 
plight of war victims. Her sensitivity was, no doubt, 
sharpened by the fact that she had undergone 
illness and bereavement herself. She had managed 
to turn her own misfortune into something very 
positive.
This experience illustrates that illnesses can serve to 
nourish one’s heart. A person who accepts his illness 
positively and perseveres through it will achieve 
greater depth and strength as a human being. 
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It also serves to remind health care professionals 
of the importance of providing constant warm 
encouragement to their patients in addition to dealing 
with the actual disease itself. Encouragement does not 
simply mean unreasonably telling the patient that an 
illness can be cured completely. It means not giving 
up on the patient as a human being even when the 
disease cannot be cured. This experience emphasises 
the importance of encouraging patients to develop the 
strength of mind that enables the patient to rise above 
an illness and achieve great satisfaction despite the 
disease still being present. 
Lessons from the life of Helen Keller 
The positive interaction between mind and body is 
well-illustrated in the lives of many people, some well-
known while others, less so. They all demonstrate the 
fact that the severity of a physical handicap varies 
according to the person’s emotional reaction to it. 
Blindness and deafness, for example, may seem to 
be completely physical problems. However, does the 
handicap result in loss of hope or does it become a 
challenge to be overcome? Helen Keller was a shining 
example of someone who had attained great heights 
despite being physically handicapped.
Helen Keller was born in Alabama in 1880. At the age 
of nineteen months, she was afflicted by an acute life-
threatening illness that eventually left her blind and 
deaf. The years that followed were hellish for her family. 
There was no way to communicate with the young 
child. Imprisoned in her body, lonely in a silent world 
and unable to tell others her feelings and wishes, Helen 
would often rage about like a wild animal. 
Helen’s life was transformed when she met her teacher, 
Anne Sullivan, who was herself partially blind. There 
was a significant moment when Helen first realised 
that things around her had names. It was the moment 
when Ann Sullivan placed one of Helen’s hands in a 
stream of water and then spelled the word water into 
her other palm. 
Helen described her feelings at that moment in her 
autobiography, The Story of My Life:
“I stood still, my whole attention fixed upon the motions 
of her fingers. Suddenly, I felt a misty consciousness as 
of something forgotten – a thrill of returning thought; 
and somehow the mystery of language was revealed to 
me. I knew then that ‘w-a-t-e-r’ meant that wonderful 
cool something that was flowing over my hand. 
That living word awakened my soul, gave it light, hope, 
joy, set it free! There were barriers still, it is true, but 
barriers that could in time be swept away” (26). 
From that moment onwards, Helen continued to make 
astounding progress. She eventually graduated from 
college and dedicated herself to helping the blind and 
handicapped.
Helen Keller’s story is a testimony to the powerful 
interaction between mind and body, and shows that 
the remarkable potential latent within the life of a 
single determined individual need not be held back 
by physical disability. Conversely, even if someone 
has great physical strength, but lacks a resolute spirit, 
he cannot reach the full potential of full play to his 
abilities. 
Helen’s story also contains an important lesson for 
health-care professionals. Her moment of break-
through, related above, is now well-known but it 
was actually only possible because of something 
less well-known but equally important - Ann 
Sullivan’s patience and her belief in Helen’s potential. 
Helen had initially rejected any contact with Ann 
Sullivan, but as a result of Sullivan’s painstaking 
effort to reach out to Helen, a warm and solid 
relationship of trust was forged which enabled the 
break-through to occur. Doctors, nurses, teachers and 
indeed everyone who has the responsibility to care 
for a patient, have much to learn from the courageous 
example shown by Ann Sullivan. 
Strength of the mind in the face of terminal 
illness 
Terminal care is an area where careful consideration 
of the mind is of great importance but sadly, often 
forgotten. 
T was an eleven-year old girl who died of leukaemia 
a few years ago in the University of Malaya Medical 
Centre. Coming from another part of Malaysia, it 
was not easy for her to adapt to life in Kuala Lumpur 
while having to come to terms with the reality of her 
diagnosis. In the beginning, she fell into depression 
and shut herself up from other people. Over the 
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subsequent months, however, she developed a great 
realisation. She realised that the quality and significance 
of one’s life is not necessarily dependent only on its 
length, but increases in proportion to the depth in 
which one lives one’s life and the value one creates. 
It was a remarkably profound and mature realisation 
for any person, let alone for a child of her age. Young 
children, especially sick ones, often have thoughts that 
are more profound than we can ever imagine.
During the last year of her short life, she was 
determined to do something useful with her life. She 
decided to challenge herself to do well in her primary 
school examinations. Although her illness resulted 
in her missing a lot of school, her determination 
was strong and she gave everything she had to her 
studies. 
As Helen Keller once said, “When we do the best 
that we can, we never know what miracle is wrought 
in our life, or in the life of another”. T’s parents and 
many friends around her age were greatly moved 
and encouraged when she managed to obtain 
four distinctions in the examination, in spite of 
her illness. It was not the examination result itself that 
was most important but rather it was the tenacity of 
her spirit and the determination not to be defeated by 
her illness that really moved others. 
Just before she died, she expressed a wish to attend 
university. Although some may call her unrealistic, one 
cannot help but marvel at the resilience and positivity 
of her spirit. T eventually grew weaker and, finally, 
passed away. Although weak and diseased, she had a 
peaceful countenance at death. One’s appearance at 
death is a good indicator of one’s state of mind.
At a time when a disease is incurable, it is easy for 
both patient and doctor to harbour feelings of futility 
and uselessness. There is also a temptation to carry 
out desperate, heroic acts. There is much for both 
doctors and nurses to learn from the courageous 
attitude of this young patient in facing death. This 
experience shows how important it is for care-givers 
to be sensitive and to carefully consider a patient’s 
state of mind in the final moments of life. It is a grave 
mistake to separate the mind from the body and 
consider only the physical disease. This can lead to 
treatment being administered to terminally-ill patients 
excessively and unreasonably, thereby causing more 
pain and anguish. Such an attitude also leads to despair 
and loss of hope for both the terminally ill patient and 
care-giver when all medical treatment is futile. 
There is an important difference between the courage 
to look the truth in the face, accepting the fact that 
all living things must die while creating value out of 
the remaining days of life, and the typically arrogant 
pathological view that life and death should be subject 
to our will, desire and control. 
Conclusion — Looking towards the future
Evidence, both laboratory and clinical, is accumulating 
that the mind and the body interact very closely. 
Concepts concerning the relationship between mind 
and body are moving from dualism to inseparability. 
True health must include both the physical body and 
the mind. 
With regard to children’s health, this article emphasizes 
that an important obligation of adults today is to 
create the conditions in the family, the school and in 
society for children to grow up happily with healthy 
bodies and minds. Giving adequate time to the child 
and listening with concern to whatever he or she has 
to say, is essential if we wish to understand the world 
of our children and help them.
One of the most important implications of our 
understanding of the interaction between the mind 
and body is an appreciation of the tremendous 
potential that exists in the life of each individual. 
We have seen examples that the strength of the 
heart or mind is an important key to release this 
energy. Therefore, in addition to offering the best of 
medical and surgical therapy, it is essential to fully 
engage the patients’ own ability to mobilize the forces 
of mind and body in their battle against illnesses. 
With regard to this, it is the bond of trust between 
care-giverand patient, between one human being 
and another, that most of all, can help the patient to 
strengthen the power of the mind. 
To ensure that future generations of doctors, nurses 
and other health-care professionals realize the full 
significance of these points and appreciate the dignity 
of life is one of the most important tasks of a medical 
school. Dr. Norman Cousins once emphasised that one 
of the biggest needs in medical education today is to 
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attract students who are well-rounded human beings; 
who will be interested in people and not just in the 
diseases that affect them; who can comprehend the 
reality of suffering and not just its symptoms; whose 
prescription pad will not exclude the human touch. In 
essence, what is needed is a profound reverence for the 
dignity of life as expressed poetically in the following 
words by Dr. Daisaku Ikeda: 
There is something vaster
than the wide open sky—
and that is, my life
There is something deeper
than the fathomless sea—
and that is, your life.
There is something more precious
than all the treasures of the universe—
and that is, our lives (27).
(This article is based on an inaugural lecture delivered 
on 26th May 2009 at the University of Malaya)
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ABSTRACT:
Distress has become a major issue in cancer population. Patients may suffer from either physical, 
psychological distress or both. Cancer patients who are undergoing chemotherapy are more likely 
to experience psychological distress. This could be due to the negative effects of chemotherapy 
agents, the uncertainty of post-treatment, and the occurrence of psychosocial problems. As a 
result, the patient may experience a normal reaction such as sadness or may develop common 
psychiatric disorders such as depression and anxiety. (JUMMEC 2010; 13(1): 12-18)
KEYWORDS: psychological distress, anxiety, depression, cancer, chemotherapy
Introduction
Psychological distress is the uncomfortable emotional 
response to a perceived harmful event such as upon 
receiving a diagnosis of cancer. “Distress” is the 
most commonly used term in oncology literature to 
describe the whole range of negative psychological 
responses experienced by the cancer patients (1,2). 
It has been defined as “a multifactorial unpleasant 
emotional experience of a psychological (cognitive, 
behavioral, emotional), social, and/or spiritual nature 
that may interfere with the ability to cope effectively 
with cancer, its physical symptoms, and its treatment” 
(3,4).
A lot of research has been done in determining 
psychological distress in cancer patients (5-7). The 
prevalence of long-term psychological distress 
in cancer patients ranges from 20% to 60% (8,9). 
It is due to the inconsistencies of study methods 
such as the assessment tools used and study 
populations included. Among the various types of 
psychological responses, anxiety and depression 
received most attention in the studies of cancer 
patients (10). Anticipatory anxiety and post 
traumatic stress disorder are the two types of 
anxiety known to be related to the initiation and 
consequence of cancer treatment (10-13). Depression 
encompasses a spectrum that ranges from normal 
sadness to major depressive disorder. It is an 
understandable reaction to the fear of cancer and 
closely linked with the somatic complaints and its 
treatment (10). 
Chemotherapy is the most frequently used treatment 
modality in cancer patients. It is well-known in 
causing a wide range of side effects such as nausea 
and vomiting, tiredness or fatigue, sore mouth, 
reduced fertility, peripheral neuropathy, and skin 
problems (14,15). It leads to high level of distress 
and impacts on the quality of life in cancer patients 
receiving chemotherapy. As people live longer after 
treatment for cancer, attention turned to the 
survivor’s quality of life and the distress that they 
may experience (10). As a result, it is important to 
monitor the psychological well—being in this group 
of patients as part of the routine care (4). It can be 
achieved by increasing the awareness and proficiency 
of oncology health care provider in recognizing and 
instituting optimal treatment for psychological distress 
in cancer patients. 
Psychological distress in cancer patients who are on 
treatment, particularly chemotherapy, need to be 
determined and understood (16). This is the primary 
focus of this article.
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Factors Related to Psychological Distress in 
Cancer Patients
Before we discuss the psychological issues that 
arise in patients receiving chemotherapy, we need 
to understand the factors related to psychological 
distress in these patients. It was described by 
Andrykowski et al that psychological distress is due 
to the imbalance between two variables (17). The first 
variable is the “stress and burden” perceived by the 
cancer patients. It disrupts the psychological health 
of a patient. The second variable is the “resources” 
available to cope with the stress and maintain the 
psychological equilibrium (17). Various patient and 
disease characteristics that were found to be potential 
risk factors for psychological distress increase 
the burden experienced by the cancer patients. 
For example, the number of stressful life events, 
previous history of depression and premorbid 
psychiatric status (18). 
Similarly, those factors that reduce the resources to 
cope with stress will result in higher psychological 
distress in cancer patients. Marital status, social 
class and financial status were predictors of high 
psychological distress which reduce the coping 
resources of a cancer patient (19, 20). A study on 
patients who underwent chemotherapy in Malaysia 
suggested that the prevalence of psychological distress 
determined by a “distress thermometer” was 51%. 
Distress was significantly associated with psychosocial 
problems (16). Another interesting example is 
the effects of age on emotional distress after a 
mastectomy. The results revealed that younger women 
apparently have resources that protect them against 
depression, although they are more likely to fear 
the recurrence of the disease and they worry more 
about disfigurement resulting from surgery. It 
conflicted with other studies that suggest marriage is 
protective against distress during stressful life events 
(21).
Normal Response to the Stress of Cancer
Rasmussen and Elverdam described cancer as a 
“symbol of disruption of life and time, and the harmony 
of ordinary life disappears” (22). The psychological 
response toward a life threatening disease such as 
cancer varies between individuals. It begins with 
shock and disbelief, followed by a mix of negative 
psychological responses and somatic complaints. 
Most people will recover from the emotional turmoil 
and recollect the psychological equilibrium (2,17). 
The period of recovery relied on the support from 
family, friends, personal coping skill and physician for 
those who opt to have a treatment plan that offer hope 
(2,23). 
Some individuals do not fully recover and continue 
to have a low level of psychological distress which 
persists for weeks or months. For some, the condition 
deteriorates and leads to marked physical, psychological 
and social impairment and subsequently requires 
psychiatric treatment (17). An early study found that 
53% of these patients were adjusting normally to 
stress; the remaining 47% had apparently clinically 
psychiatric disorders. Of the 47% with psychiatric 
disorders, 68% had adjustment disorders with 
depressed or anxious mood, 13% had a major 
depression, and 4% had a preexisting anxiety disorder 
(21).
Anxiety
Anxiety is well documented in patients with the 
diagnosis of cancer and the initiation of treatment 
(10-13). Patients are confronted with the worry 
of death at the time of diagnosis. It leads to a 
substantial level of anxiety. Gradually, it is followed by 
the fear of recurrence, disrupted belief of life expectancy 
and loss of focus in living (22, 24-28). The initiation of 
treatment such as chemotherapy add further emotional 
burden to the patients, which attributed to the 
potential adverse effects. There are two specific anxiety 
disorders, namely anticipatory anxiety and post-
traumatic stress disorder (PTSD), which are believed 
to be closely linked with the treatment of cancer that 
significantly affect the patient’s functioning, compliance 
and quality of life (10-13, 22, 24, 29).
Nausea and vomiting are common side effects 
of chemotherapy. It leads to several physical 
complaints such as loss of appetite and weight. The 
subsequent development of psychological nausea 
and vomiting which is known as anticipatory nausea 
and vomiting (ANV) is widely studied (10-13, 30-37). 
The common explanation for ANV is conceptualized 
as a learning process (38). The stimulation during 
drug administration followed by the drug related side 
effects triggers a conditioning process. As a result, 
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nausea and vomit are experienced during the next 
cycle of treatment even before drug administration. 
Autonomic reactivity and conditionability of an 
individual play distinct roles in determining the 
risk of developing ANV during chemotherapy (36). 
Patients with trait anxiety and post-treatment 
nervousness have a higher risk of ANV (35). Other 
predicting factors for ANV found in previous studies 
are younger age, history of susceptibility to motion 
sickness and history of side effects from previous 
chemotherapy (37). Understanding of this concept 
is important for health care providers who provide 
screening and treatment of ANV in cancer patients 
who are receiving chemotherapy. 
Another specific type of anxiety that received 
much attention in the study of cancer patients is 
PTSD. The reported prevalence ranges from 18-80% 
depending on the time period of study and severity 
of the disorder (39-41). A study that used stringent 
diagnosis criteria for cancer related PTSD in breast 
cancer patients after completion of treatment 
shown that the prevalence rate was as low as 3% 
(42). However, before considering the biological 
explanation for PTSD in cancer patients, we need 
to accept that the diagnosis of cancer or treatment 
resembles a typical type of event or trauma that 
gives rise to PTSD (24). An abrupt disclosure of 
the diagnosis of cancer and the administration 
of treatment closely represent a traumatic event 
comparable with the disease itself which is an ongoing 
stress for an individual.
Many studies, which look into the underlying 
neuroendocrinologic processes that lead to PTSD 
in cancer patients has been conducted (43-45). 
Previous studies found that there were corticotrophin 
releasing factor (CRF) hypersecretion with relatively 
low level of adrenocorticotropic hormone (ACTH) and 
cortisol in cancer related PTSD. Negative feedback 
inhibition was hypothesized by Yehuda to explain this 
hypothalamic-pituitary-adrenal (HPA) alteration in 
PTSD (43). Another interesting finding was the lower 
amygdala volume in PTSD patients (44-45). These 
biological changes were suggested to trigger the 
emotional response and persistent of anxiousness 
in patients with PTSD. The patients re-experience 
and have persistent intrusive thoughts or memories 
of the traumatic events. The knowledge regarding 
the causative process of PTSD is helpful in the 
development of treatment for this group of patients. 
Depression
Cancer is recognized as a significant psychosocial 
stressor and predisposes to depression. Many 
researchers have assessed depression in cancer patients 
in the past decades and the reported prevalence 
varies significantly because of the varying diagnosis 
criteria, measurement or rating scales used and 
differences in the study populations (21, 46-49). 
Based on the study by Derogatis et al, 6.1% of the 
cancer patients met the criteria for major depressive 
disorder (21). According to the review article by 
Mc Daniel et al, the figure was higher for cancer 
inpatients which is 8% and 15 to 36% for all 
depressive disorders (46). The prevalence also 
determined by the site of cancer. It is highly 
prevalent in oropharyngeal and pancreatic cancer but 
less common in gynaecological and lymphoid cancer 
(50).
There was a long standing debate on the diagnosis 
of depression in cancer patients (21). It is due to the 
overlapping of somatic symptoms in depression 
with the physiological symptoms in cancer and 
its treatment such as fatigue, loss of appetite 
and weight, sleep difficulties, poor memories and 
concentration. This group of symptoms was referred 
to as “sickness syndrome” by the recent researchers 
and believed to be caused by the pathophysiological 
process of the cancer and its treatment (51, 52). 
It involved the activation of immune system and 
proinflammatory cytokine system and lead to 
depression in cancer patients (51-53). 
Increased level of stress hormone, cortisol and 
hyperactivity of the stress system were another 
hypothesis suggested as the pathophysiological 
process of depression (24,54). It is associated with 
the progress of cancer and affects the treatment 
outcome by lowering the defense mechanisms (55). 
It is recognized that the treatment of depression is 
beneficial regardless of the etiology of the “sickness 
syndrome” (56). 
In addition, arousal (alertness vs boredom) and 
valence (positive vs negative) are two dimension of 
emotion that could predict fatigue and depression in 
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patients undergoing chemotherapy (57-60). This was 
the pathophysiologic explanation that depression is 
associated with stress response system. 
Depressed patients were more likely to develop anxiety, 
fatigue and insomnia. It leads to non compliance, 
refusal of treatment, poor quality of life and shortened 
life expectancy (61, 62). A study shown that only 
51.3% of breast cancer patients with concomitant 
depression accepted and received the proposed 
chemotherapy as comparing to the 92.2% of the 
control group (63). 
It is often reported that the recognition of psychiatric 
need in cancer patients is poor among health care 
providers. There were fewer than half of the patients 
with cancer related depression symptoms were 
offered treatment (64-67). Health care providers 
do not prioritize mental health issues and lack of 
effective communication with patients is the two main 
reasons of under-recognition and under-treatment 
of depression in cancer patients (64, 65). Depression 
is a progressive condition and it responses better 
to treatment at the earliest phase because of the 
nature of the alteration in the neurological process 
(68, 69). Oncology health care providers should be 
more proficient in psychosocial assessment and 
able to detect subtle signs, monitor risk factors and 
reduce depression in cancer patients. Adequate 
management of depression required the consistent 
and informed involvement of health care providers 
and caregivers (69). This will improve the quality of 
care and reduce the psychological distress in cancer 
patients.
Conclusions
The significant experience of psychological distress 
among cancer patients undergoing chemotherapy 
should not be left unrecognized and untreated. 
Factors that concern the patients should be addressed 
accordingly, and in doing so, there may be a need for 
a multidisciplinary approach. Therefore, the role of the 
mental health team in managing cancer patients is 
very important.
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ABSTRACT: 
The clinical experience of the novel drug temsirolimus on eight patients with metastatic renal cell 
carcinoma and who were refractory to other forms of treatment is reported. Although none of the 
patients showed complete or partial response, three patients had stable disease. One patient was 
prematurely withdrawn due to pneumonitis. Five patients died during the period of observation 
of twenty months and the median survival time from start of treatment was ten months. Three 
patients showed no evidence of adverse events (AE). Five patients showed dyslipidemia and two 
had pneumonitis for which, the drug had to be withdrawn in one of them. None had significant 
leucopenia. We conclude that temsirolimus has activity even in heavily pretreated patients in 
advanced renal cell carcinoma and in addition, has the benefits of ease of administration and 
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Introduction
Renal cell carcinoma (RCC) represents 2-3% of all 
cancers and there appears to be a gradual increase in 
its incidence (1). It is often diagnosed late and distant 
metastases are present in more than one-third of 
cases. It is usually asymptomatic and the classic triad 
of flank pain, gross haematuria and palpable abdominal 
mass is now a rarity (2). A very important prognostic 
indicator is its stage (3). Of the histological types the 
clear cell type is the commonest, occurring in about 80 
to 90% of cases (4).
Nephrectomy is the primary treatment of choice. But 
in the presence of metastatic disease conventional 
chemotherapy, radiotherapy or even immunotherapy 
are ineffective. Molecular targeted therapy is 
recommended (5). The first line therapy for patients 
with good to intermediate prognosis has been 
sunitinib or sorafenib. Interleukin-2 and interferon 
alpha alone or in combination have also been used. 
In patients with poor prognosis temsirolimus is 
recommended (6). Its effective use in advanced 
renal cell carcinoma has been observed in Phase 2 
trials and improved survival reported in phase 3 trials 
(7, 8).
The main objective of the study was to assess our 
experience of temsirolimus in patients with advanced 
renal cell carcinoma who were treated in a local setting 
as per standard of care. In particular the objectives 
were three. 
Firstly, it was to assess the efficacy of temsirolimus 
in terms of the number of patients deriving clinical 
benefit in a group of patients with advanced disease 
and who were not responsive to other treatment 
modalities. Secondly, to assess the incidence, type and 
degree of adverse events seen and thirdly, to assess the 
survival rate following treatment with temsirolimus in 
this small group of patients 
Methods
The case records of eight patients with advanced renal 
cell carcinoma and who were treated with temsirolimus 
were reviewed. All patients had nephrectomies and 
some form of prior treatment. Such treatment included 
either radiotherapy, alpha-inteferon, sunitinib, 
sorafenib or pazopanib.
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Patients were administered intravenous temsirolimus 
25mg as an intravenous infusion over no less 
than 30 minutes but with completion of infusion 
within 60 minutes. Premedication with intravenous 
diphenhhydramine 25 to 50 mg was given about 30 
minutes prior to treatment. The treatment was repeated 
weekly up and until either the drug had to be stopped 
due to toxicity or if there was disease progression. 
Clinical benefit was defined as the patient having 
complete response, partial response or if they remained 
in stable disease. No benefit was when the patient 
went on to progressive disease after a minimum of 
eight doses of temsirolimus or when the drug had 
to withdrawn due to toxicity. Response to treatment 
was assessed based on clinical grounds and where 
indicated, radiologically either by x-rays or CT scans. 
The adverse events were recorded and graded 
according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTC AE 
v3.0) (9). Survival was based on all-cause mortality.
Results
There were eight patients with advanced and 
metastatic renal cell carcinoma who were treated 
with temsirolimus. Their clinical characteristics are 
summarized in Table 1. All had lung metastases at the 
time of commencement of treatment. Most had prior 
treatment with either interferon, sunitinib, sorafenib or 
pazopanib. 
patient Age (years) gender histology stage at diagnosis prior treatment
site of metastasis at start of 
temsirolimus
1 57 Male Clear cell 1 Interferon Lungs, 
bone adrenal
2 31 Male Clear cell 3 Sunitinib Lung, 
bone, 
lymph node, 
adrenal
3 44 Male Clear cell 2 Sunitinib,
Sorafenib
Pazopanib
Lung, 
lymph nodes
4 55 Male Clear cell 3 Sunitinib, 
Sorafenib
Lung
5 51 Male Clear cell 3 Radiotherapy
Sunitinib
Lung, 
bone,
adrenal
6 50 Female Clear cell 4 Chemotherapy
Sunitinib
Lung
7 46 Male Clear cell 2 Interferon
Pazopanib
Lung
8 47 Female Clear cell 4 Interferon
Interleukin
Sunitinib
Dendritic cell vaccine
Bevacizumab
Sirolimus
Lung
Table 1: The demographic and clinical characteristics of the patients in the study
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There were seven patients who had completed a 
minimum of eight doses. One patient had died after 
three doses were given i.e. patient number 4. In terms 
of response, none of the patients showed complete or 
partial response. However, three patients had stable 
disease while on treatment i.e. patient number 5, 6, 
and 8. The remaining four patients showed either 
progressive disease or died soon after eight does of the 
drug were given. 
Of the eight patients, three showed no evidence of 
adverse events (AE). In the remaining five patients the 
number of patients affected, type, grade and outcome 
of the adverse events seen is summarized in Table 2. 
Of interest was the relatively frequent incidence of 
some form of dyslipidemia. All these patients were 
non-dyslipidemic before treatment. Also seen were 
two cases of pneumonitis ; in one, the drug had to be 
withdrawn temporarily and in the other after 20 doses 
were given. The implications of these findings are 
discussed. 
Five patients died during the period of observation 
and their survival pattern in this group of patients is 
shown in Figure 1. The median survival time from start 
of treatment was ten months.
Discussion
Metastatic renal cell carcinoma is a therapeutic 
challenge because of its poor response to conventional 
chemotherapy and radiotherapy. Over the last few 
years, three agents that target critical signaling 
components involved in tumor angiogenesis and 
tumor cell proliferation—sorafenib, sunitinib and 
temsirolimus have been approved for use in metastatic 
renal cell carcinoma. While the first two agents 
have been recommended as first or second line 
treatment for all patients, temsirolimus has been 
recommended as first line only for patients with poor 
prognosis (5,6).
The results of the present study show that although 
none of the eight patients showed complete or partial 
response to temsirolimus, three patients had stable 
disease. It must be remembered that these patients 
were patients with metastatic disease and who did 
not respond to other treatment. Notwithstanding, 
Number of 
patients Adverse event (AE) grade* treatment
Action to study 
drug outcome
2 Leucopenia 1 None Continued Resolved
2 Pneumonitis 1 & 3 Symptomatic Stopped Resolved
3 Mouth ulcer 1 Symptomatic Continued Resolved
3 Rash over arm face and neck 1 Symptomatic Continued Resolved
4 Hypercholesterolemia 1 & 2 Fenofibrate Continued Resolved
1 Deranged liver function tests 3 None Stopped temporarily Resolved
2 Hyperlipdemia 1 & 2 Fenofibrate Continued Resolved
1 Dry mouth/stomatitis 1 Symptomatic Continued Resolved
1 Chest discomfort 1 Symptomatic Continued Resolved
1 Photosensitivity 2 Avoid light/creams Continued Resolved
1 Facial edema 2 None Continued Resolved
1 Dry tongue/stomatitis 1 Symptomatic Continued Resolved
1 Alteration to taste 1 None Continued Unresolved
1 Epistaxis 1 Symptomatic Continued Resolved
1 Hyperpigmentation over 
arms and buttocks
1 None Continued Resolved
* 1 = mild AE; 2 =moderate AE; 3 = severe AE; 4 = life threatening or disabling AE; 5 = death related to AE
Table 2: Adverse events seen in the patients
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the overall median survival rate was 10 months from 
commencement of treatment. 
In a multicentre trial involving 626 patients with 
previously untreated poor-prognosis metastatic renal 
cell carcinoma receiving either alpha-inteferon alone, 
temsirolimus or a combination of the two showed that 
when compared to alpha interferon , temsirolimus 
improved the survival rate. The addition of interferon 
did not make any difference to the survival rate (8). Of 
interest was that the survival in the temsirolimus only 
treated group was similar to ours being close to 10.8 
months . 
The pharmacological action of temsirolimus is novel. 
It is an antineoplastic agent that acts as a selective 
inhibitor for mTOR(mammalian target of rapamycin) 
kinase (10), a signaling pathway involved in the growth 
and proliferation of cells. Temsilorimus, a rapamycin 
analogue, acts as a selective inhibitor of mTOR by 
binding to an intracellular protein (FKBP-12) and the 
protein-drug complex binds and inhibits the activity 
of mTOR that in turn controls cell division (11). High 
concentrations result in complete cell growth inhibition 
in vitro, whereas inhibition mediated by FKBP12/
temsirolimus complex alone results in approximately 
50% decrease in cell proliferation. Inhibition of mTOR 
activity results in a G1 phase growth arrest in treated 
tumour cells resulting from selective disruption of 
translation of cell cycle regulatory proteins such as 
D-type cyclins , c-myc and ornithine decarboxylase. 
When mTOR activity is inhibited, its ability to 
phosphorylate and thereby control protein translation 
factors that control cell division is blocked. The anti-
tumour effect of temsirolimus may also in part arise 
from its ability to depress levels of hypoxia-inducible 
factors (HIF) and vascular endothelial growth factor 
(VEGF) in the tumour microenvirionment and thereby 
impair vessel development (12). 
Notwithstanding its novel pharmacological actions, 
like all anti-neoplastic agents, its adverse reaction may 
have been of concern. However, in our small sample of 
patients no adverse events were seen in three patients. 
None of the patients had significant leucopenia. The 
majority of the patients had only Grade 1 severity and 
was easily managed with supportive care. Of interest 
was the relative frequency of some form of dyslipdemia 
and interstitial lung disease. These adverse effects are 
known (13) and others have had similar experience 
(14,15)). The mechanism for hyperlipidemia remains 
unclear but presumably, being an mTOR inhibitor it 
is involved in lipid metabolism. The mechanism of 
development of pneumonitis is also unclear although 
Figure 1: Kaplan-Meier Survival pattern of eight patients
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T-cell mediated delayed type hypersensitivity 
mechanism has been proposed (15). Treatment had to 
be discontinued in both our patients, one temporarily 
and the other after 20 doses were given. In the other 
patient with deranged liver function tests it was only 
temporarily withdrawn. 
The recommendations are that temsirolimus be 
reserved as the first line only for patients with poor 
prognosis (6). Based on the results of our albeit small 
sample, we have shown that temsirolimus has activity 
even in heavily pretreated patients and it has the 
added benefits of ease of administration and good 
tolerability. The results of more randomized controlled 
trials are needed to confirm whether it has a role even 
in patients with good prognosis and more importantly 
to determine optimal sequencing of targeted agents 
and their role in adjuvant therapy (16). 
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ABSTRACT: 
Despite being the major cause of cancer-related death in Malaysian women, local data on 
patterns of breast cancer relapse and their long term outcomes are still scarce. We conducted 
a retrospective study on all patients treated for non-metastatic invasive breast cancer in 1999-
2000 at the University of Malaya Medical Centre (UMMC), who subsequently developed relapse. 
We sought to analyse the patterns of relapse, their associated clinicopathological features and 
the overall survival ratefollowing the relapses. Univariate and multivariate analyses were used to 
analyse demographics and clinicopathological factors. Survival was analysed using the Kaplan 
and Meier method and compared by the log rank test. A total of 268 patients with a mean age 
of 50, were identified for the study. At a median follow-up of 50 months, 73 patients (27.2%) 
had relapsed. Local, regional and distant relapse rates were 5.5%, 1.9% and 19.8% respectively, 
whereas, the 5-year survival rates were 61%, 40% and 21% respectively (p < 0.01). Most relapses 
occurred within the first five years of diagnosis. Patients with long disease-free interval had better 
survival. The most common distant relapse site was the lungs while bone was the distant relapse 
site with the best prognosis. Disease stage, nodal status and oestrogen receptor status were 
found to have correlation with the risk of relapse. We concluded that the survival of patients with 
relapsed breast cancer was associated with the site(s) of first relapse and the disease free interval 
and clinicopathological factors can be used to predict the risk of relapse. (JUMMEC 2010; 13 (1): 
24-32)
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oriGiNal artiCle JuMMeC 2010: 13(1)
Correspondence: 
Rozita Abdul Malik
Clinical Oncology Unit
Faculty of Medicine, University of Malaya
50603 Kuala Lumpur, Malaysia
Email: rozita_abdulmalik@yahoo.com
Introduction
Breast cancer is the most common cancer affecting 
women in Malaysia. The third issue of the National 
Cancer Registry on cancer incidence in Peninsular 
Malaysia reported 11,952 new cases of breast cancer in 
2003-2005, accounting for 31.3% of newly diagnosed 
cancers in women. Breast cancer was also the most 
common cancer in all ethnic and age groups of females 
above 15. The peak age-specific incidence rate was in 
the 50-60 years age-group (1).
Breast cancer is also the most frequent cancer in 
women worldwide. It accounts for 23% of all cancers. 
With an estimated number of 1.15 million new cases 
in 2002, it ranked second overall when both sexes 
were considered together (2). Despite the increasing 
trend in the incidence of breast cancer worldwide, 
survival has steadily improved over the recent 
decades. This may be explained by the development of 
improved treatment modalities and earlier detection as 
a result of effective screening programs and increased 
awareness among women. Nevertherless, breast 
cancer remains as the leading cause of death in women 
worldwide (3). 
The aim of treating of non-metastatic invasive breast 
cancer is to cure. Management of breast cancer in 
UMMC was evidence-based and later guided by the 
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Ministry of Health Clinical Practice Guidelines on 
‘Management of Breast Cancer’ which was issued 
in December 2002 (4). The treatment involves a 
multidisciplinary team which includes breast surgeons, 
clinical oncologists, pathologists, radiologists and 
other allied health personnel.
Non-metastatic breast cancer has the tendency 
to relapse despite adequate curative therapy. The 
site(s) and the timing of relapse are important 
determinants of outcome in relapsed breast cancer. 
They also play a significant role in determining the 
appropriate management of the patients. Local 
and/or regional relapse may still be suitable for 
curative local treatment, whereas patients with 
distant relapse are usually offered systemic therapy, 
with palliative intent. The risk of relapse may be 
estimated based on the clinical and pathological risk 
factors. Due to this risk, patients are given long term 
follow-up after completing all curative treatment. 
In 2006, Elder et al. reported the results of a study 
on the patterns of breast cancer relapse of 2509 
patients treated at Strathfield Breast Centre (TSBC) 
in Australia (3). They found that most relapses 
occurred within the first five years of diagnosis, with 
the greatest risk between one to two years from 
primary surgery. The relapse rate was 18% and bone 
was the most common site of relapse. The prognosis 
was dependent on the timing and site(s) of relapse. 
Late relapses resulted in better survival compared to 
early relapses. They reported a 5-year survival rate 
of 41%, 20% and 13% for local, regional and distant 
relapse respectively. In patients with distant relapse, 
the survival rate after relapse in the bones was higher 
than in the viscera. Two other studies by Imkampe et 
al. and Giordano et al. also showed similar outcomes 
based on the sites of relapse (5, 6). 
Furthermore, these studies also showed the important 
role of clinicopathological factors in determining 
breast cancer outcome. Higher stage, large tumour 
size, positive node and high tumour grade are poor 
prognostic factors associated with a higher risk of 
relapse (3, 5, 6).
In 2008, Taib et al. reported the survival outcome 
of 413 Malaysian women with breast cancer 
diagnosed between 1993 and 1997 at the UMMC. 
The objectives were to analyse the overall survival 
and the prognostic factors that affect survival. 
They suggested that ethnicity may be one of the 
significant prognostic factors in addition to stage, 
size of tumour, nodal status and tumour grade in 
influencing survival (7). Oestrogen receptor (ER) status 
was not found to be a significant prognostic factor in 
this study.
A study conducted at the University of Texas 
involving 647 patients showed that ER status had 
a significant effect on the rate and likely sites of 
relapse (8). ER negative had a significantly higher 
rate of relapse compared to ER positive. There was 
a significantly higher rate of relapse in the viscera 
and soft tissues in ER negative patients whereas 
ER positive status was associated with a higher rate of 
relapse in the bones.
Currently, there is no available published data on 
the patterns of breast cancer relapse in Malaysia. 
Therefore, this study was performed to analyse the 
patterns of breast cancer relapse and the prognosis 
following relapse.
Methodology
This was a retrospective study conducted on all 
women diagnosed with non-metastatic invasive 
breast cancer in UMMC between 1st January 1999 
and 31st December 2000. Patients who defaulted on 
surgery or adjuvant treatment were excluded from the 
study. Those who developed relapse were selected for 
further analysis.
Data on patients’ demography, clinicopathological 
factors, treatment and relapses were obtained 
from available records. Survival data was 
obtained from the National Registry of Birth and 
Death. Patients who did not come for follow-
up were contacted to determine their current 
status. Uncontactable patients were deemed as 
‘unknown’. Staging of cancer was based on the 2002 
Tumour Node Metastasis (TNM) classification of 
Malignant-Tumours by the American Joint Committee 
on Cancer (AJCC).
Site of relapse was categorized into local, regional 
or distant. Local relapse is occurrence of relapse 
either in the conserved breast or the chest wall 
of patients who had undergone mastectomy. 
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Regional relapse is disease recurring in the regional 
lymph nodes either in the ipsilateral axillary, 
supraclavicular or infraclavicular fossa. Distant 
or systemic relapse refers to distant metastases. 
Relapses were recorded according to the first or 
most significant site of relapse. Simultaneous local 
and regional disease is categorized as regional 
relapse while any simultaneous occurrence 
of distant relapse with local or regional disease was 
categorized as distant relapse. 
Disease free interval (DFI) was defined as the time 
from the date of primary breast cancer surgery 
to the date of relapse. Overall survival was defined 
 
Table 1: Patient Demographics
 
Variable n=268 %
Age
< 40 
40-49 
50-59 
≥ 60
27 
127 
62 
22
10.1 
58.6 
23.1 
8.2
Ethnic group
Malay 
Chinese 
Indian 
Others
53 
174 
37 
4
19.8 
64.9 
13.8 
1.5
tumour size
≤ 2 cm
> 2 and ≤ 5 cm
> 5 cm 
Unknown
95 
139 
33 
1
35.4 
51.9 
12.3 
0.4
Axillary nodes status
Positive 1-3 
Positive 4-9 
Positive > 10 
Negative
82 
36 
16 
134
30.6 
13.4 
6.0
50.0
histologic grade
G1 
G2 
G3 
Unknown
25 
107 
80 
56
9.3 
39.9 
29.9 
20.9
oestrogen receptor status (Er) 
Postive 
Negative 
Unknown
147 
104 
17
54.9 
38.8 
6.3
types of surgery 
BCS 
Mastectomy
72 
196
26.9 
73.1
as the time from the date of relapse to death of 
any cause. Analysis of the overall survival according 
to site of distant relapse was carried out on 
patients with only one site of distant relapse. 
Univariate and multivariate analyses were used 
to analyse demographics and clinicopathological 
factors. Overall survival was analysed using the Kaplan 
and Meier method and compared by the log rank 
test.
Results
Patient Demographics
A total of 268 patients diagnosed with non-metastatic 
invasive breast cancer were identified. The mean age 
was 50 (range 26-81). Chinese ethnic group scored 
the highest incidence rate followed by Malay and 
Indian. The most common tumour size was between 
2 and 5cm. Half of the population had positive axillary 
lymph node involvement at diagnosis. The most 
prevalent tumour grade was grade 2 followed by 
grade 3 and grade 1. More than 50% of the patients 
were ER positive. Majority of patients underwent 
mastectomy (73.1%) while the remainders had breast 
conservation surgery (BCS) (Table 1).
Following BCS, only 81.9% had adjuvant radiotherapy 
(RT) to the conserved breast whereas half of the patients 
who underwent mastectomy received adjuvant RT. 
Most patients received adjuvant systemic therapy 
which included either chemotherapy or Tamoxifen or 
both (Table 2).
Table 2: Types of adjuvant therapy 
Adjuvant treatment
types of surgery
bCs 
n = 72(%)
Mastectomy 
n = 196 (%)
Radiotherapy  
Systemic therapy #
59 (81.9) 
65 (90.3)
132 (67.3) 
186 (94.9)
Note: Some patients received both radiotherapy and systemic 
therapy for adjuvant treatment, hence the total percentages are 
greater than 100%.
# Includes chemotherapy and tamoxifen 
Patterns of relapse 
At a median follow up of 50 months (range 5 
-107 months), 73 patients (27.2%) developed 
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relapse. A total of 15 patients (5.5%) had local 
relapse, 5 patients (1.9%) had regional relapse and 
53 patients (19.8%) had distant relapse. Within 
the distant relapse category, 22 patients (41.5%) 
had more than one site of relapse and lung 
was the most common site of distant relapse (47.2%) 
(Table 3 and 4).
The median DFI was 29 months (range 1-92 
months). The relapse rate was 3.7% at 12 months 
after surgery, peaked to 9.7% at 24 months and 
later declined to 2.4% at 36 months. The risk of relapse 
declined steadily after five years to less than 5.0%, as 
shown in Figure 1.
Clinicopathological factors associated with 
relapse
Logistic regression analyses showed that stage, axillary 
node and oestrogen receptor status had statistically 
significant correlation with relapse, with p=0.001, 
p=0.001 and p=0.042, respectively. The data are 
illustrated in Table 5 below (Table 5).
Table 3: Relapse rate 
sites of relapse n = 268 %
Not relapse 
relapsed
Local relapse
Regional relapse
Distant relapse
195 
73
15
5
53
72.8
27.2
5.5
1.9
19.8
Table 4: Number of relapse according to sites of distant relapse 
sites of distant relapse Number of patients %
Bone
Lung
Liver
Brain
Others
24
25
8
9
9
45.3
47.2
15.1
16.9
16.9
Note: Patients may have more than one site of distant relapse, hence 
the total percentage is greater than 100%.
*Other sites involved were ovary, peritoneum and adrenal gland
 
Figure 1: Yearly risk of relapse after primary surgery for breast cancer
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Overall Survival
Overall survival according to disease free 
interval
More than half of the relapses (56.2%) occurred 
within the first 36 months after primary surgery. This 
duration was subsequently chosen to differentiate 
between short (less than 36 months) or long (more 
than 36 months) DFI in this study population. Short 
DFI resulted in lower overall survival rate than long DFI 
(p < 0.001) (Figure 2).
Overall survival according to sites of relapse
Patients with only local relapse had the best prognosis 
with a 5-year overall survival of 61% compared 
to patients who developed regional or distant 
relapse with 40% and 21% 5-year overall survival rate 
respectively (p < 0.01) (Figure3).
Overall survival according to sites of distant 
relapse
Two-year overall survival rate for patients with bone 
metastasis only was 61% compared to 20% in those 
with lung metastasis. None of the patients with liver 
or brain metastasis were alive at 2 years while patients 
with relapse at other sites had 2-year overall survival of 
50% (Figure 4).
Discussion
This study involved 268 patients with the mean age of 
50 years (range 26-81 years). The highest incidence was 
in the Chinese ethnic group and this is consistent with 
the Malaysian NCR 2003-2005 report (1). 
Approximately 18.1% of patients who had BCS in 
this study population did not receive adjuvant RT, 
either due to patients’ refusal or reasons unknown. 
RT to the residual breast is a standard indication 
after a BCS to reduce the risk of relapse in the 
conserved breast. Two thirds of the patients who had 
mastectomy received RT. Of particular note was the 
high proportion of systemic treatment given following 
the BCS (90.3%) or mastectomy (94.9%). These figures 
are higher than as compared to the study done by 
Elder et al. which reported 62.7% of BCS and 70.7% of 
mastectomy patients receiving systemic treatment 
(3). This may be explained by the larger proportion of 
Table 5: Number of relapse according to clinicopathological factors of primary tumour
Characteristics total no. of patients (X)n = 268
No. of patients with relapse (y)
n = 73
percentage
y/X x 100%
Stage
1
2
3
69
121
78
12
27
34
17.4
22.3
43.6
tumour size
≤ 2 cm
> 2 and ≤ 5 cm
> 5 cm 
Unknown
95
139
33
1
20
39
14
0 
21.1
28.1
42.4
0.0
Axillary node status
Node positive 
Node negative
134
134
48
25
35.8
18.7
tumour grade
Grade 1
Grade 2
Grade 3
Unknown
25
107
80
56
5
30
30
8
20.0
28.0
37.5
14.3
oestrogen receptor status
Positive
Negative
Unknown
147
104
17
34
37
2
23.1
35.6
11.8
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Figure 2: Overall survival according to disease free interval
Figure 3: Overall survival according to sites of relapse
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patients with higher stage disease in this study who 
require adjuvant systemic treatment. Furthermore, 
more than half of the study population had ER positive 
disease and therefore received tamoxifen as part of the 
systemic treatment. 
The relapse rate in this study was 27.2% with 
local, regional and distant relapse rates of 5.5%, 
1.9% and 19.8% respectively. Elder et al. reported 
a lower relapse rate of 18% with local, regional 
and distant relapse rates of 4.9%, 1.0% and 11.4% 
respectively (3). The higher relapse rate seen in 
our patients may be explained by more patients 
with higher stage disease who were at a higher risk 
of developing relapse. Stage 3 disease in this study 
was 29.0% compared to 3.9% from the study by 
Elder et al (3). The most common site of distant 
relapse was the lung which accounted for 47.2% 
of cases followed by bone, liver, brain and other 
sites. 
Majority of relapse occurred within the first five years 
from primary surgery, in agreement with published 
data (3). The highest risk of relapse was between 
one to two years from surgery (9.7%) and beyond 
five years, the risk of relapse decreased steadily. 
The median DFI in this study was 29 months. If 
patients have not relapsed within the first five years of 
surgery, the likelihood of relapsing thereafter is very 
small. However, patients with a history of breast cancer 
suffer excess mortality for more than 30 years after 
surgical therapy (9).
Figure 4: Overall survival according to sites distant relapse.
Note: Analysis was done on patients with only one site of distant relapse.
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Similar to the findings by Elder et al. and 
Imkampe et al (3, 5), tumour stage, axillary node 
involvement and oestrogen receptor status were 
found to have statistically significant correlation 
with relapse in this study. Patients with higher 
tumour stage, positive nodes and oestrogen receptor 
positive status were more likely to relapse. However, 
the correlation between tumour grade and relapse 
was not significant, (p=0.07). This could be due to 
high proportion of unknown grade (14.3%) in the 
relapsed cases in this study population and the reasons 
for this was unclear. 
DFI was an important prognostic factor for breast cancer 
relapse. Patients who had relapse after 36 months 
had better survival rate than those who relapsed 
earlier. The difference in survival was statistically 
significant (p < 0.001) and consistent with other studies 
(3). 
Patients with local relapse had better prognosis 
compared to regional and distant relapse. The five-
year overall survival for patients with local, regional 
and distant relapse were 61%, 40% and 21%, 
respectively. The overall survival was higher compared 
to the study by Elder et al. which quoted 41% for local 
relapse, 20% for regional and 13% for distant relapse 
(3). There were 11 patients (15.1%) who did not come 
for follow-up and were not contactable. Therefore, 
they were deemed as ‘unknown’. This could be one 
of the reasons for the overall higher survival rate 
seen in this study. Another reason could be due to 
effective treatment delivered to patients with relapse 
but this needs further studies to confirm. For those 
with local relapse, about 66% had salvage surgery 
and they were still alive until the end of the study. 
This may explain the relatively good overall survival for 
local relapse.
Bone metastases had better prognosis than visceral 
metastases (3, 5). In this study, two-year overall survival 
for bone metastases was 61%, lung metastases was 
20% and 0% for those with liver and brain metastases. 
The reasons for the relatively better prognosis of 
bone metastases are still unclear. A randomized study 
looking at the clinical course of bone metastases 
for breast cancer reported that bone metastases 
were more common in receptor positive or well 
differentiated tumours which are associated with 
better prognosis (10).
Limitations and Recommendations
This was a retrospective study, therefore, the 
documentation in the case notes were not 
standardised and some data were missing or 
incomplete. The study sample was relatively small 
compared to other studies.
To ensure more reliable and accurate data, a prospective 
study with larger sample size, longer duration and 
a longer follow-up is recommended. A mechanism 
which allows a continuous data collection through 
a prospective database, either at an international 
or a national level, would be beneficial.
Conclusions
Most relapses occur within the first five years of 
diagnosis and patients with late relapse have better 
survival than early relapse. Survival of patients 
with relapsed breast cancer is associated with 
the site of first relapse. The prognosis is better for 
local and regional relapse compared to distant 
relapse. Clinicopathological factors are useful to 
predict risk of relapse in patients with breast cancer 
after completing treatment.
Disease relapse is one of the worries faced by patients 
with breast cancer after completing their curative 
therapy. Data on patterns of relapse and its prognosis 
is both important and useful to clinicians when 
discussing long term outcome with the patients. This 
is the first study to provide data on breast cancer 
relapse in Malaysia. The results will be an invaluable 
information for our clinicians in the management and 
counselling of patients with breast cancer.
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Introduction
With over 100 years of research, it is now well known 
that breast cancer is a disease driven by hormones, 
genetics (sex, body compositions, genes), and lifestyle 
(1). Studies showed that there is a rapid increase in 
incidence rates of breast cancer before menopause 
(ages 40–50) and then a decline in rates (2). Women 
are now living longer with breast cancer, and may be 
dealing with numerous intimacy-, relationship-, and 
sexuality-related issues, including those related to 
reproduction (3), especially so for younger women (4, 
5). The prevalence age of breast cancer onset amongst 
Malaysian women are generally younger at 40-50 years 
compared to developed countries. 
Sex plays an important role, beside its basic function for 
procreation, in enhancing interpersonal relationships, 
and building a more intimate, meaningful bond. 
Managing the medical tasks, and the modifiable factors 
(like diet, weight, physical activity) are important (2, 6, 
7-10), but these should be complemented with patient 
self management of emotional tasks as well as role 
and relationships. American Cancer Society found that 
cancer survivors were not pursuing healthy lifestyles 
(11), and equally important, they need to pursue happy 
lifestyle behaviors. In fact, evidence shows that having 
a general feeling of happiness and optimism has a 
“protective effect” on the etiology of breast cancer 
(OR-0.75, 95% CI:0.64-0.86) (12). In short, issues of 
sex and sexuality are integral components of human 
behavior, adding romance, enjoyment and enhancing 
the quality of life of women. However, in the traditional 
Asian clinics, sexuality is still neglected, and/or takes 
a back seat to cancer treatment and survival issues in 
people with cancer. Even in the more developed Asian 
countries, like Japan, a study on breast cancer patients 
(n=102) found that discussing body image and 
sexuality were disregarded in therapeutic decision-
making situations (13).
Cancer treatment and altered sexual functioning
Normal aging, by itself can greatly impair the sexual 
functioning of humans. Sexuality amongst men have 
gained a bit more attention where hypothetical surveys 
even suggest that men express a willingness to trade 
away survival time just so they can preserve or improve 
their sexual function (Singer PA, Tasch ES, Stocking 
C, et al 1991). Studies show an increase incidence of 
erectile dysfunction in men without cancer, up to 
threefold between the fifth and eighth decades of life 
(Feldman HA, Goldstein I, Hatzichristou DG, et al , 1994), 
whilst one-third of older men report experiencing 
a significant impairment in sexual function (Litwin, 
1999). Do women have the same significant concerns 
and issues of sexual functioning? Studies have 
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documented that approximately 50% of women who 
have experienced breast or gynecologic malignancy 
have serious concerns regarding sexual functioning 
(14), whereby sexual complaints can occur in up to 
90% of women with a history of a cancer diagnosis 
(15). It appears that a diagnosis of breast cancer have 
further compounded whatever negative impact of 
normal aging on sexual functioning of women. One 
study found that sexual functioning of women (n=558) 
who received chemotherapy compared to those who 
did not, regardless of the type of surgery (p<0.001) was 
significantly affected (16). Many women are distressed 
by treatment-related sexual function or fertility-related 
adverse effects of treatment, but they are reticent 
to bring up the topic of sexuality given their lack of 
experience and low self-confidence, especially among 
the younger women (17). 
Specifically, breast reconstruction has been shown to 
be associated with loss of breast sensation (18), whilst 
both mastectomy (with or without reconstruction) and 
lumpectomy were associated with altered body image; 
potentially affecting sexuality (18, 19), a decrease in 
perceived sexual attractiveness and reduced sexual 
interest (20). Radiation therapy causes changes in 
breast sensation, fatigue or arm mobility. (21), whilst 
Tamoxifen therapy is linked to pain, discomfort and 
vaginal tightness during intercourse (22). Women 
undergoing chemotherapy have experienced ovarian 
failure, hormonal changes, menstrual cycle disruption, 
amenorrhea, vaginal dryness and atrophy, and 
decreased sexual arousal and desire (23).
The issues of sexual dysfunction amongst women
 In four focus groups conducted with Malaysian 
women living with breast cancer (n=39), a rising 
theme was on the neglect of sexuality issues (24).  In 
one of the groups, the women were quite open about 
their intimate relationships with their husband. This 
dispels the notion that Malaysian women in general 
are reluctant to talk about their private lives. However, 
as this was not typical in all groups, the use of focus 
groups may have led to their openness regarding the 
topic. These women’s expressions negate the current 
belief that patients do not want to discuss about 
sexual issues. Sexuality and intimacy were two main 
role-related themes that emerged consistent as an 
unmet need across the groups. In general, the women 
felt that their intimate relationships were affected to 
some extent, but they felt the main reason was ‘within 
themselves’ rather than with their spouse whom they 
reported as being ‘encouragingly supportive’. Some 
women seek clarifications and asked, ‘Can we still have 
sex?’ - as if sex after breast cancer will bring about 
detrimental consequences either on themselves or 
their spouse. In fact, one spouse of the informant came 
forth with his query on the toxicity of chemotherapy 
during sexual act of intimacy. While some utterances 
from the women may seem to be exaggerated, this 
issue of sexual concerns does seem to weigh heavily 
on both the survivors and their spouse’s minds. Myths 
surrounding the issues of intimacy, chemotherapy 
and sexuality were not uncommon across the groups. 
Factors like age and side effects of hormonal treatment 
causing dryness; (including myths that too much 
excitement can trigger the cancer cells, and toxicity of 
chemotherapy can ‘travel’ to their spouse during sexual 
intercourse) were revealed (24). Acute or chronic 
sexual function problems resulting from treatments 
such as mastectomy, lumpectomy, radiation, and 
chemotherapy are not uncommon. The excerpt below 
highlights some examples of common myths related to 
chemotherapy and cancer. 
“My husband believed that with chemotherapy, I have the 
toxins all over my body, so it’s better not to have it (sexual 
intercourse)”. 
 “I heard that cancer patient cannot have too much 
sex because I heard that sexual excitement can lead to 
recurrence, and I want to know if it’s true or not?” 
Cancer is a debilitating illness. It robs years from life 
and life from years because it traumatizes and detracts 
confidence, self-image, feelings of worth and pride, 
and the sense of normalcy from the survivors’ daily 
functioning. One study examining the sexual problems 
of women below 50 years (n=209), revealed specific 
problems in four areas (lack of interest in sexual 
activity, difficulty in becoming aroused, difficulty 
relaxing and enjoying sex, and difficulty achieving 
orgasm), with a lack of interest being the main 
challenge (25). These needs are critical but have been 
ignored in our traditional medical model care delivery 
system. Sexual functioning, like other functioning, 
needs to be viewed as fundamental to health and 
quality of life. Thus, management of cancer care must 
be emphasized as incomplete without full attention to 
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the women’s personal responses and experiences to 
illness, including sexual function. However, literature 
shows that hormonal and pharmacological therapies 
have been marketed to treat sexual desire and arousal 
disorders, and many if not none have been approved 
by the FDA nor have any been proven effective by 
clinical trials (26)
Counseling Sexual Issues With women
Psycho-behavioral intervention is a key part of the 
comprehensive sexual dysfunction treatment schema. 
In order for it to be comprehensive, an educational 
program that fosters open discussions regarding 
concern is a start. Healthcare professionals are often 
too embarrassed or feel ill-equipped to discuss 
sexual issues and patients are too embarrassed to 
ask (27). These issues of sexual functioning are often 
viewed as a difficult issue to handle when caring for 
patients. The topic is often absent from the curricula 
of most medical and health schools, as well as 
residency programs and fellowships program. This 
may explain why many healthcare professionals 
feel ill-equipped to address issues of sexuality 
during the course of routine health care and in the 
management of women with cancer. Any changes, for 
it to take effect, must target at the policy levels and to 
ensure health intervention are sufficiently broad 
based to address the vast needs (including addressing 
issues related to cultural myths) of the service users. 
It is especially pertinent to discuss sexuality issues 
with women – at before, during, and after cancer 
treatment. Therapists and health professionals in the 
oncology community need to sharpen their diagnostic 
and therapeutic skills in this area of sexuality 
counseling. 
Counseling with survivors of breast cancer may start 
with  the broad range of sexual function concerns 
that survivors as a group may experience, including 
fear and myths, genital pain, lack of lubrication, 
satisfaction, arousal, and desire, and then ask if 
the survivor has questions about any of these 
or would like information or referrals for additional 
information. Strategies like local non-medicated, non-
hormonal vaginal moisturizers including vitamin E 
suppositories agents, used two to three times weekly, 
can provide alternative relief for the symptoms of 
vaginal atrophy by maintaining the elasticity and 
pliability of the vaginal mucosal lining (28). Sexual 
function, body image, and relationship problems 
experienced by women due to breast cancer and 
cancer treatments may be addressed via individual 
and interpersonal counseling (29). A sensitive, open-
minded, and forthright attitude about issues of sexual 
functioning is timely when caring for women with 
breast cancer. Sexual counseling helps normalize 
the experience of sexual problems after cancer 
treatment, and can be effectively conducted in 
group work and/or further one-to-one intervention 
if needed. Conscious effort must be made to allow 
patients a safe environment to vent their fears, 
and provide the reassurance needed. A sexual 
psycho educational program in an oncology setting 
is necessary to provide comprehensive care to the 
patient. There is much to learn from the field of 
counseling which is deeply rooted in social-humanistic 
sciences. Overall, a bio-psychosocial model of care, 
in place of the stifle, traditional-hierarchical medical 
model of care can provide the foundation for 
addressing the much neglected aspect of sexual 
functioning amongst patients. 
Conclusion 
Breast cancer affects quantity and quality of life 
and every aspect of functioning, including sexual 
influences, the ultimate goal being to facilitate 
the readjustment of women towards independent 
functioning and meaningful living despite a diagnosis 
of breast cancer. In addressing the unmet sexual needs 
of women and providing counseling about changes in 
sexual functions, as well as therapeutic tips to enhance 
sexuality, healthcare professionals must be aware that 
they are treating the patient as a whole and not just 
the cancer. 
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brEAstfEEdINg prACtICEs IN A rUrAl  
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ABSTRACT: 
Breast feeding has been actively encouraged in Malaysia in the last few years in all public 
hospitals. This study proposes to find out the prevalence of breast feeding in three villages 
in a rural community in Kedah, Malaysia. This was a cross sectional study on breastfeeding 
practices in Kubang Pasu, a district of Kedah. Majority of the mothers initiated breast  
feeding but exclusive breastfeeding was only 21% for four months and predominant 
breastfeeding was about 12.6%. The breastfeeding practice was more prevalent among women 
from the higher educational strata and higher income than those from the lower strata and lower 
income (p<0.05). Mothers with a positive attitude on breastfeeding and those who possess a 
higher knowledge were associated with a longer mean total duration of breastfeeding (p<0.05). 
Spouse and family members played an important role in building up a mother’s confidence to 
breast feed her child. Majority of the mothers received breast feeding information before birth 
from mainly the doctors and nurses. Older mothers, house wives and mothers with formal 
education practiced a longer duration of breast feeding (p<0.05). The study also showed that 
there is an increase in the knowledge of breast feeding among the mothers and that they 
have a positive attitude to breastfeeding. Most of the mothers initiated breast feeding early  
and they received support on breastfeeding from the nurses and doctors. (JUMMEC 2010; 13 (1): 
38-44)
KEYWORDS: exclusive breastfeeding, predominant breastfeeding, rural Malaysia
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Introduction
Feeding practice during infancy is an important 
determinants of future physical and mental well-being 
because of rapid growth spurt and developmental 
of organ and tissue occurring during the first year of 
life (1, 2). They vary with socio-economic stratification 
and are regulated by a variety of factors such as 
education, custom beliefs and taboos (1, 3). 
Breastfeeding is the optimal feeding practice for infants 
in view of its benefits to both children and mothers. 
The advantages of breastfeeding include fulfilling the 
nutritional needs of infants, immunological protection, 
bacteriologic ally safe, minimal allergic reaction, 
economical, mother to child bonding, increased birth 
spacing and many others (4, 5). UNICEF estimated that, 
if every baby was exclusively breastfed from birth up 
to 6 months, 1.5 million lives would be saved each 
year (6, 7). Thus in 1981 the World Health Organization 
(WHO) introduced the code of ethics to safeguard 
the marketing practices which are detrimental to 
breastfeeding.
The WHO Global Data Bank on Breastfeeding 
presently covers 94 countries and 65% of the world’s 
infant population (<12 months). Based on the latest 
data, it is estimated that 35% of these infants are 
exclusively breastfed between 0-4 months of age. In 
South-East Asia, the ever-breastfed rate has increased 
somewhat in recent years, for example in Thailand 
it increased from 90% in 1987 to 99% in 1993. The 
increase in exclusive breastfeeding rates is due 
mainly to breastfeeding campaigns, and additional 
Baby-friendly Hospitals and trained breastfeeding 
counselors (8)
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In Malaysia, active national promotion on breastfeeding 
began since 1976. Early local studies documented 
that breastfeeding is widely practiced in rural areas, 
particularly among Malay mothers (9, 10, 11, 12). Recent 
findings from Sarawak reported that more children are 
being breastfed than in earlier decades. However, the 
median duration of breastfeeding is similar to that of 
earlier researches in Peninsular Malaysia i.e. 3 months 
(13). 
This purpose of this study is to assess the prevalence of 
breastfeeding practices among women of reproductive 
age (15–49 years old) in three selected rural villages in 
Kubang Pasu District, Kedah and also to investigate 
the relationship between the attitude of the mother 
towards breast feeding and the duration of breast 
feeding.
Materials and Methods 
This was a cross sectional descriptive study on practices 
of breastfeeding and it was conducted in three rural 
areas, namely Kampung Keda Wang Tepus, Kampung 
Changkat Setol and Felda Bukit Tangga in Kubang 
Pasu, Kedah. The kampungs were selected due to the 
cloosness to the health centres. The selection criteria 
may have introduced a bias in the study. The study was 
conducted from 8-15 June 2005. The inclusion criteria 
for our sample was women in their reproductive age 
(15 – 49 years old) with at least one living child aged 
two years old, regardless of their marital status. Every 
woman was randomly selected from a household 
who fulfilled the criterion was included in the study. 
A household may report one or more respondents. 
However, women who were unable to breastfeed due 
to serious illnesses (heart disease, cancer, nephritis, and 
active or untreated TB, HIV or AIDS, active herpes lesions 
on the breast and severe malnutrition) were excluded 
from this study. The interview was a face-to-face using 
a structured questionnaire. The questionnaire was pre-
tested at the Obstetric & Gynaecology and Paediatrics 
Wards in Hospital Tengku Ampuan Rahimah, Klang to 
minimise errors. Errors related to the understanding 
of ever breast fed, exclusive breast fed were modified 
so that the mother understood their meaning. Despite 
this there were problems for the mothers to understand 
as some of them were uneducated. The collected data 
was then coded, computed and analysed using the 
SPSS version 10. The knowledge on breastfeeding 
among the respondents was assessed based on a 
list of 12 true-or-false statements. These statements 
were further categorized into 3 categories namely 
benefits of breastfeeding (5 statements), techniques of 
breastfeeding (4 statements) and contraindications of 
breastfeeding (3 statements). The Chi-square test was 
used to determine the associations and the level of 
significance was set at p<0.05.
Figure 1: Age distribution of Respondents 
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Results
There were 115 mothers who fitted the inclusion 
criteria and they were interviewed face to face. 
Majority of the mothers 111 (96%) respondents were 
married. Only 3% of them were widowed and one 
respondent was a single mother. Figure 1 shows that 
the age distribution of female respondents who fall 
within the reproductive age group of 15 to 49 years old. 
The majority of mothers 49 (42.6%) were aged between 
45 to 49 years age group. Mothers aged between 
35 to 39 years comprised 17 (14.8%) of the study 
population, followed by the age group of 25 to 29 years 
16 (13.9%), 40 to 44 years 15 (13.0%), 30 to 34 years 
13 (11.3%) and 20 to 24 years 5 (4.4%).There were no 
young respondents aged between 15 to 19 years. All 
respondents interviewed were Malays since they were 
from a rural area in Kedah.
Most of the respondents 43 (37%) had primary level 
of education. This was followed by lower secondary 
28 (24%) and upper secondary level education 23 
(20%). Meanwhile, a total of 16 (14%) respondents were 
not educated formally or only had informal education. 
Only 6 (5%) received tertiary education. More than 
half of the respondents 69 (60%) were unemployed. 
This group included a majority of homemakers, which 
is not uncommon in a kampung setting. A total of 24 
(21)% of the total study population were employed. 
Self-employed respondents were those that involved 
in home businesses e.g. seamstress. They made up of 
about 22 (19 %) of the study population. 
The mean income per capita for the study population 
was RM206. In Figure 2 about 75 (54.8%) of the study 
population was found to have an income per capita 
of below RM 200. In contrast, there was only 2 (1.74%) 
who earned between RM600 and RM800. 
Knowledge on Breastfeeding
The 12 point questionnaire to find out the knowledge 
level of the mothers was used and the results are shown 
in Figure 3. Three respondents or 2.6 % of mothers 
managed to obtain a perfect score of 12. There were 
no mothers who scored below 3. Those who scored 7 
and above were considered to have high knowledge 
on breast feeding and those who had 6 or lower were 
considered to have low knowledge.
Half of the total respondents 55 (47.8%) correctly 
answered all 5 statements regarding the benefits of 
breastfeeding. Out of 4 statements regarding the 
techniques of breastfeeding, most respondents 46 
(40.0%) scored 50% i.e. 2 statements were correctly 
answered. A high knowledge was considered to be 
more than 7 correct answers and the low level of 
knowledge was considred to be 6 and below.
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Attitudes towards Breastfeeding
Of the 115 respondents who were interviewed, a total 
of 113 (98%) mothers had positive attitude regarding 
the practice of breastfeeding. Only 2% of them were not 
sure. None felt that breastfeeding was not beneficial. 
Reasons for Breastfeeding
Most mothers 75 (65.2 %) cited child’s health as 
the main reason for breast feeding. The next most 
popular reason was that ‘breastfeeding is more 
economical’ which was cited by about 17 (14.7 %) of 
the mothers. This was followed closely by 15 (13.3 %) 
who said that ‘breastfeeding strengthens the bond 
between my child and me,’ and about 10 (9.3 %), cited 
‘convenience’ and only 8 (7.3 %), cited that ‘breast 
milk is nutritious’ and 4 (3.3%) cited mother’s health’ 
and others e.g. prevention of cervical cancer, religious 
reasons 3 (2.6%). 
Breastfeeding Practice
Almost all the mothers 114 (99%) initiated 
breastfeeding but exclusive breast feeding for a 
period of 4 months was only by 24 (21.0%) of the 
mothers and predominant breastfeeding practice 
(breast feeding with addition of water) was about 
14 (12.2 %) and complementary breast feeding 
(breast feeding with addition of food or fluid) was 75 
(65.2%). Majority of the mothers 53 (46.0%) breast fed 
between 20 to 30 months whereas 25 (21.7 %) breast 
fed between 10-20 months and about 28 (24.3 %) 
breast fed between 0- 10 months. There were only 
8 (7.5%) who breast fed after 30 months. A large 
proportion of mothers 104 (90%) received support to 
breastfeed their child while only 11 (10%) of them did 
not. The main source of support was from their spouses 
42 (36.5 %), followed by family members 40 (35.4%), 
health personnel 27 (23.4 %) and others like. friends 
and neighbours constituted only 6 (5.2%).
Information on Breastfeeding 
About 110 mothers (96.0%) received information on 
breastfeeding and only a minority of them 5 (4%) had 
never been informed. From the informed group 83 
(79%) of them obtained information before the birth 
of their child whereas about 18 (16.6%) received it 
after birth of their child only and 5% received both 
before and after delivery. In this section, respondents 
were required to rank the following three sources 
of information i.e. mass media, family members and 
health personnel with 1 being the least helpful and 
3 being the most helpful. Approximately 92 (80%) of 
mothers felt that health personnel (e.g. maternity ward 
nurses and doctors) were the most helpful source of 
information and about 90 (78%) of mothers listed mass 
media as the least helpful source (p>0.05).
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Relationship between age and duration of 
breastfeeding
Most of the mothers in the older age group i.e. > 32 years 
to 49 years old practiced breastfeeding for a longer 
duration when compared to the younger mothers 
(< 32 years) breastfed for a shorter time (p<0.05). 
Therefore the duration of breastfeeding, whether 
exclusively or otherwise, increases with the mother’s 
age. 
Relationship between educational level and 
duration of breast feeding
Mothers who received formal education tend to 
breastfeed longer compared to uneducated mothers or 
those who were educated informally. Education plays 
an important part in increasing the awareness among 
mothers on the benefits of breast milk to both mother 
and child (p<0.05).
Relationship between occupational status and 
duration of breastfeeding
Unemployed mothers including homemakers 
practiced breastfeeding for a longer duration with 12 
(17 %) of them breastfeeding for about a year while 36 
(52 %) mothers breastfeeding for more than a year. In 
contrast, a shorter duration was noticed among 
employed and self-employed mothers. This result is 
not surprising as many mothers claimed that lack of 
time at home prevented them to breastfeed their child 
(p>0.05).
Relationship between financial status and 
duration of breastfeeding
Figure 4 shows that mothers with a higher financial 
status (RM600–RM799) have a lower mean duration 
of breastfeeding (19.83 months) when compared with 
mothers with lower income. As breast milk is more 
economical compared to infant formula milk, therefore 
mothers who earn a lower income in this area have a 
tendency to breastfeed longer period of time although 
this findings is not significant (p>0.05).
Relationship between attitudes of mothers and 
duration of breastfeeding 
The relationship between attitude of the mothers and 
duration of breastfeeding.was assessed . There were 
no mothers with a negative attitude, all agreed that 
breastfeeding is good for the baby and the mother. 
Among mothers who felt that breastfeeding was 
good, a majority of them 80 (69.5%) respondents tend 
to breastfeed longer. Only 2 mothers were unsure 
and both of them still breastfed for more than a year 
(p>0.05).
Figure 4: Relationship between Financial Status and Duration of Breastfeeding 
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The relationship between knowledge on 
breastfeeding and duration of breastfeeding 
As shown above, mothers who scored more than 
50% in more than seven correct answers in the 
knowledge questions demonstrated a longer duration 
of breastfeeding. This could be due to the fact that 
mothers who are aware of the benefits, techniques and 
contraindications of breastfeeding would naturally 
breastfeed longer (p>0.05).
Discussion
Majority of the mothers 114 (99%) in the rural villages 
of Kedah ever breastfed their children and this finding 
is consistent with findings from earlier studies (1, 10, 
12) on the practice of breastfeeding in rural areas 
which reported a prevalence of more than 90%. A 
more recent study (6) of an urban community in 2002 
revealed a high prevalence of 99.3%. 
However, the incidence of exclusive breast feeding 
in this study was only 21% while predominant breast 
feeding and complementary feeding was higher. A 
similar survey in Kubang Pasu Maternal and Child 
Health Centre in 2004 mothers in the district found 
similar results.However the national health and 
morbidity study (NHMS) in 2006 found the exclusive 
breast feeding to be 14.9%. A high proportion or 
46% of the mothers breastfed their children for 
an average of 20 to 30 months in this study. Most of 
them who initiated breastfeeding were homemakers 
or unemployed and they had low monthly income 
and received some formal education up to primary 
school level (p<0.05). The educational level, working 
status and income level of the families were not 
found to be significantly associated with the duration 
of breastfeeding in this study (p<0.05). In another 
survey, breastfeeding duration was significantly 
higher among mothers with primary education 
compared to those with tertiary education (3, 14). 
However, a study by Siah & Yadav (6) proved otherwise. 
Low educational level, lack of social exposure and 
mobility in many ways restrict the career choices and 
capability of these women. As a result they are tied down 
to perform traditional women’s role as housewives and 
breastfeeding practice is commonly expected of them. 
However, it cannot be overlooked that breastfeeding is 
a rational and natural choice by the mothers, and apart 
from being a traditional practice, breastfeeding is also 
encouraged by Islam, the religion of the community.
This study also showed that mothers with a reasonably 
high knowledge (more than 7 correct answers) on 
breastfeeding do so for a longer duration of time i.e. 
more than a year and those who reflected a positive 
attitude towards breastfeeding tended to breastfeed 
longer. This shows that knowledge and attitude play an 
important role in one’s decision to breast feed and also 
the duration of breastfeeding. A high percentage of 
mothers felt that the most helpful source of information 
on breastfeeding comes from health personnel e.g. 
doctor, nurses and staff in the maternity ward. This 
proves that the government’s efforts in promoting and 
educating the public on breastfeeding are showing 
signs of success. 
However, while most mothers were aware of the 
benefits of breastfeeding, many were still unsure about 
the correct technique and conditions or practices that 
contraindicated breastfeeding. Incorrect breastfeeding 
methods can affect the initiation, pattern and duration 
of breastfeeding besides reducing the mothers’ 
confidence and breastfeeding skills when faced with 
repeated failure to express milk. Furthermore, multiple 
unproductive trials leave the babies unsatisfied, 
frustrated and in return irritate or discourage the 
mothers. In contrary, successful breastfeeding 
eventually raises the confidence and evokes interest in 
mothers who feed their children with milk from their 
breasts. 
Clearly, the knowledge and attitude of breastfeeding 
among the mothers is interrelated and it provides a 
positive feedback to each other. However, ignorance 
of breastfeeding can lead to undesirable medical 
conditions such as infant infection. 
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ABSTRACT: 
Night work and rotating shift work are found to be detrimental to the health of workers. A cross 
sectional analytical study was conducted among the employees of a public medical centre in 
Kuala Lumpur. A total of 380 employees participated in the health screening and questionnaire 
survey. The majority of the respondents were Malays, females, and with mean age of 49 years old. 
The shift workers persistently had higher but non-significant proportions of being overweight/
obesity and unhealthy clinical indicators such as systolic and diastolic blood pressure, fasting 
blood glucose and lipid profile except waist circumferences and HDL-cholesterol. There were  
also slightly more shift workers diagnosed with diabetes mellitus, hypertension or coronary 
heart disease (p>0.05). Although the present study could not provide established evidence for a 
relationship between shift work and cardiovascular risks, this could serve as a pilot study for future 
studies in this area. (JUMMEC 2010; 13 (1): 45-49)
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Introduction
Shift work is an employment practice designed to 
make use of the 24 hours of the clock, rather than a 
standard working day. The term shift work includes 
both long-term night shifts and work schedules in 
which employees change or rotate shifts (1). Night 
work and rotating shift work disrupt the circadian 
timing system. This disruption may produce significant 
deleterious symptoms in some workers. Certain 
medical conditions may be aggravated by shift-work 
scheduling, and shift workers are at increased risk of 
experiencing cardiovascular, gastrointestinal, and 
reproductive dysfunction (2-4). However, shift work is 
a requirement of nursing and essential health workers 
to provide patients with optimum levels of continuous 
care in health care settings. 
Shift work has been associated with an increased risk 
of cardiovascular disease (CVD). Findings showed 
that non-day workers had a relative risk (RR) for 
all circulatory diseases of 1.31 (95% CI 1.06-1.63) 
compared to day workers (5). The increased risk of 
CVD associated with shift work is related to the greater 
incidence of Metabolic Syndrome (MetS) among 
these workers. The metabolic syndrome incidence 
was found to be significantly higher in shift workers 
than in other workers (OR: 4.10, 95% CI 1.34-12.55) 
who were healthy at baseline (6). The MetS incidence 
rate among shift workers (60.6 per 1000 person-years) 
was increased in comparison with day workers (37.2 
per 1000 person-years) with an odds ratio (95% CI) 
of 1.77 (1.34-2.32) (7). A study by Copertaro et al (8) 
showed a high prevalence of metabolic syndrome 
detected among shift workers. The above could be 
explained by evidence that a significant relation 
was found between years of working nights 
(more than 10 years) and high cholesterol values 
(RR=2.58; CI=1.07-6.27) (9). Positive relationship was 
also observed between BMI and waist to hip ratio 
(WHR) and duration of shift work experience, with an 
adjustment for age (10). 
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Therefore, a study should be conducted among all 
employees of hospitals or medical centres to investigate 
the relationship of shift work with health particularly 
cardiovascular risks. This paper attempts to explore the 
association of shift work with the cardiovascular risks 
among employees of a public medical centre in Kuala 
Lumpur. 
Materials and methods
This was a cross-sectional study conducted in 2005 
to 2006. Universal sampling was conducted where all 
employees aged 40 years and above of the university’s 
medical centre were invited to participate in 
the health screening and questionnaire survey. Ethics 
clearance was obtained from the Ethics Committee 
of the medical centre that governed all studies 
involving humans. Informed consent was obtained 
from all respondents. 
All respondents were required to fast overnight for 
the screening of biochemical indicators including 
lipid profile (total cholesterol, triglycerides, HDL-
cholesterol, LDL-cholesterol) and fasting blood glucose. 
Venous blood was obtained following standard 
procedures by medical officers of the staff health 
clinic from the medical centre. All analyses of blood 
samples were conducted by the Clinical Diagnostic 
Laboratory of the same medical centre. 
Anthropometric measurements (weight, height 
and waist circumference) and a self-administered 
questionnaire survey were also conducted. The 
questionnaire was pre-tested and enquired on 
socio-demographic characteristics, medical history, 
occupational history (work in shifts, overtime, job 
satisfaction etc). 
 All data was entered and analysed by SPSS for windows 
version 15.0. Appropriate statistical analysis was 
conducted and the significant level was preset at 0.05. 
Results
Out of a total of 1,007 workers who had undergone 
the health screening, only 380 responded to the 
questionnaire survey (response rate of about 38%). 
Although the response rate was less than satisfactory, 
there was no significant difference observed between 
respondents and non-respondents (Table 1). 
Out of the 380 respondents, only 112 (29.5%) of them 
worked on shifts. Shift work in this medical centre 
was on rotation basis with three shifts throughout the 
24 hours. The three shifts were morning, afternoon 
and night shifts. The mean number of night shifts 
for the respondents was 3.56 ± 2.18 per month. 
There was no significant difference in race, gender, 
marital status, education level and age among the 
shift and non-shift workers (Table 2). Both groups 
were predominantly Malay, female and married 
with secondary education. The mean age of both 
groups was about 49 years old. Respondents working 
as nurses and security staff comprise the majority of 
the shift workers.
There was no significant difference in the mean BMI, 
systolic and diastolic blood pressure, fasting blood 
Table 1: Comparison of respondents and non-respondents 
Respondents
(n=380)
n (%)
Non-respondents
(n=627)
n (%)
p-value
race Malay 
Chinese 
Indian 
Others
313 (82.3) 
27 (7.1) 
39 (10.3) 
1 (0.3)
496 (79.1) 
52 (8.3) 
78 (12.4) 
1 (0.2)
0.652
gender Male 
Female
122 (32.2) 
258 (67.8)
232 (36.9) 
395 (63.1)
0.126
Age (years) mean + s.d. 49.40 ± 4.80 49.96 ± 5.22 0.09
bMI (kg/m2) mean + s.d. 27.06 ±5.00 27.00 ± 4.91 0.85
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sugar, lipid profile except waist circumference and 
HDL-cholesterol between shift and non-shift workers 
(Table 3). However, the shift workers had persistently 
higher but non-significant proportions of overweight/
obesity and abnormal clinical indicators as shown in 
Figure 1. There were also slightly more shift workers 
diagnosed with diabetes mellitus, hypertension or 
coronary heart disease but the associations were not 
significantly different (p>0.05). 
Discussion
Although the response rate was unsatisfactory, the 
baseline socio-demographic characteristics of the 
respondents and non-respondents were comparable. 
There was also no significant difference in the socio-
demographic characteristics of the shift and non-shift 
workers in this medical centre except the occupation 
status due to the nature of their work. There were more 
nurses and security guards who worked shift while most 
of the non-shift workers were in the administrative and 
non-critical fields. 
The shift workers persistently had higher proportions 
of diagnosis with chronic diseases such as diabetes 
mellitus, hypertension and coronary heart disease 
although not statistically significant different (p>0.05).
There was no significant difference found in their 
mean body mass index (BMI), systolic and diastolic 
blood pressure, and lipid profile among the 
shift and non-shift workers except waist 
circumferences and HDL-cholesterol (p<0.05). When 
these workers were divided into normal and abnormal 
groups based on all the above, the shift workers 
persistently had higher proportions of abnormal 
health indicators. These insignificant results might 
be due to the small sample size. Further study should 
be conducted on a larger sample to establish significant 
associations. 
Although some evidences had shown that working 
shifts affected the health of workers (8, 11, 12), the 
current findings did not show significant difference 
between workers who worked shift and non-shift. 
Similar results were shown by Dochi et al (13) in 
their 14-year cohort study of 5510 male workers 
in a steel company. No consistent association was 
found between shift work and hypercholesterolemia. 
A study by Morikawa et al (14) too did not find 
Table 2: Socio-demographic characteristics of shift and non-shift workers 
Shift workers
(n=112)
n (%)
Non-shift workers
(n= 268)
n (%)
p-value
race Malay 
Chinese 
Indian 
Others
92 (82.1)
 5 (4.5)
 14 (12.5)
 1 (0.9)
221(82.5)
 22 (8.2)
 25 (9.3)
 0 (0.0)
0.193
gender Male 
Female
40 (35.7)
72 (64.3)
 82 (30.6)
186 (69.4)
0.393
Marital status Married 
Single/divorced
104 (92.9)
8 (7.1)
 233 (87.5)
33 (12.5)
0.105
Education level Primary
Secondary
Diploma
Tertiary
 9 (8.0)
75 (67.0)
21 (18.8)
 7 (6.3)
 17 (6.4)
172 (64.7)
 49 (18.4)
 28 (10.5)
0.586
occupation Nurses
Medical assistants
Technician
Administrative
Security 
Attendants
52 (46.4)
 7 (6.3)
 5 (4.5)
 0 (0)
34 (30.4)
14 (12.5)
88 (32.8)
24 (9.0)
37 (13.8)
59 (22.0)
0 (0)
60 (22.4)
<0.001
Age (years) mean ± s.d 49.78 ± 4.71 49.21 ± 4.85 0.287
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significant difference in total cholesterol between 
daytime workers and shift workers. However, they 
found that shift work was considered to be a risk 
factorfor excess weight. Another study conducted 
in Malaysia among factory workers showed that 
BMI was increased among shift workers but no 
significant difference found on health indicators (15). 
According to Sharifian et al (16), shift work acted 
as an oxidative stressor in inducing medical disorders, 
while aging and obesity made them more sensitive to 
this hazardous effect. 
Therefore, shift workers’ health should be safeguarded 
through preventive check-ups and regular controls 
by occupational health physicians. This might involve 
occupational health physicians to inform shift workers 
on coping strategies, and to assess health disorders 
(17). This “higher-risk” subgroup may benefit from 
targeted interventions to reduce potential adverse 
effects from shift work (18). 
Poor response rate giving rise to a small sample size is 
the limitation faced by this study. Efforts such as mail 
Table 3: Clinical indicators of shift and non-shift workers 
shift workers
Mean ± s.d
Non-shift workers
Mean ± s.d
t-test
p-value
bMI 27.48 ± 4.75 27.04 ± 4.90 0.424
waist (cm) 91.38 ± 8.63 85.91 ± 12.00 0.036
systolic blood pressure (mmhg) 119.42 ±16.08 116.73 ± 14.07 0.108
diastolic blood pressure (mm hg) 72.81 ± 6.37 71.70 ± 6.37 0.124
fasting blood sugar (mmol/l) 5.55 ± 1.73 5.58 ± 1.89 0.883
total cholesterol (mmol/l) 5.68 ± 1.02 5.69 ± 0.89 0.900
hdl-cholesterol (mmol/l) 1.19 ± 0.31 1.29 ± 0.32 0.005
ldl-cholesterol (mmol/l) 3.79 ± 1.00 3.75 ± 0.86 0.697
triglyceride (mmol/l) 1.65 ± 1.73 1.47 ± 1.04 0.210
8.9
22.3
7.2
22.0
36.9
42.9
26.8
3.6
73.9
12.5
6.3
8.2
30.4
21.3
26.1
7.5
19.5
1.9
8.3
4.5
6.4
74.6
3.4
17.1
37.1
41.6
0 10 20 30 40 50 60 70 80
Diabetes mellitus
Hypertension 
Coronary heart disease
SBP
DBP
FBS
Tchol
HDL-C
LDL-C
Trigliceride 
Normal weight
Overweight
Obese
 
Percent
Shift workers Non-shift workers
8.9
22.3
7.2
22.0
36.9
42.9
26.8
3.6
73.9
12.5
6.3
8.2
30.4
21.3
26.1
7.5
19.5
1.9
8.3
4.5
6.4
74.6
3.4
17.1
37.1
41.6
0 10 20 30 40 50 60 70 80
Diabetes mellitus
Hypertension 
Coronary heart disease
SBP
DBP
FBS
Tchol
HDL-C
LDL-C
Trigliceride 
Normal weight
Overweight
Obese
 
Percent
Shift workers Non-shift workers
Percent
Figure1: Proportions of abnormal BMI groups, clinical indicators and diagnosis of chronic diseases among shift and non-shift workers
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reminders and telephone calls were taken to increase 
response rate. However, due to the demanding 
nature of these health care workers, most of them 
declined to participate. Both the respondents and 
non-respondents had similar socio-demographic 
background, which showed that the results are still 
generalizable to the employees of this medical 
centre.
Conclusion
Although the shift workers seemed to be at higher risk 
for cardiovascular diseases, the present study could 
not provide established evidence for a relationship 
between shift work and cardiovascular risks. However, 
this could serve as a pilot study for a better designed 
study to be conducted in the future. 
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Introduction
Complications due to drug therapy are the most 
common types of adverse reactions in hospitalized 
patients (1). Studies have shown that between 2% and 
6% of patients are hospitalized due to adverse drug 
reactions (2). These cutaneous reactions range from 
macular rash to extensive blistering lesions. Although 
a majority of cutaneous drug reactions are not severe, 
immediate recognition can prevent the progression to 
severe reactions that may result in prolonged hospital 
stay, increased morbidity and mortality and increasing 
costs due to usage of medications and laboratory 
charges (3). In a recent report, based on the findings 
from a large population of hospitalized Medicare 
patients in the United States, it was shown that those 
with adverse drug reaction, which affects only 1.73% 
of those hospitalised, incurred 9.15% more charges 
on drugs, 2.82% more on laboratory costs and had an 
8.25% increase in length of hospitalisation (3). This 
would also inevitably lead to an increase in indirect 
costs due to prolonged time off from work.
In 2008 alone, the National Centre for Adverse Drug 
Monitoring of Malaysia has received 4826 local 
reports of spontaneous adverse drug reactions, an 
increase of 57.3% in comparison to the previous year. 
The most number of adverse drug reactions were 
attributed to cardiovascular drugs, followed by use of 
antimicrobials (4). With increasing awareness of the 
health care professionals and improved reporting, it is 
predicted that the frequency and number of adverse 
drug reactions may be on the increase; more so when 
antibiotics are used indiscriminately.
Case Reports
In this report, we focus on two types of severe 
cutaneous adverse drug reactions, i.e Stevens-Johnson 
Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). 
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ABSTRACT: 
Prescribing medication is not without its adverse effects. Complications due to drug therapy 
are on the rise in Malaysia, especially when antibiotics are used indiscriminately. We reviewed 
cases admitted to the Acute Medical Ward of University of Malaya Medical Centre (UMMC), Kuala 
Lumpur, Malaysia, over a two-month period from March to April 2009. The authors found that 
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) were the most common 
severe adverse cutaneous reactions due to ingestion or parenteral use of drugs. In this report, is 
a brief description of the two conditions and ways to manage them. The authors have come to 
a conclusion that judicious use of medications with adequate patient education is important in 
order to avoid these adverse effects. (JUMMEC 2010; 13 (1): 50-58)
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We reviewed the cases admitted to the Acute Medical 
Ward of the University of Malaya Medical Centre 
(UMMC), Kuala Lumpur, Malaysia, over a two-month 
period from March to April 2009. We noted that these 
two types were the most common severe adverse 
cutaneous reactions due to ingestion or parenteral use 
of drugs.
Case Report 1
A 48-year-old Bangladeshi man presented to his 
General Practitioner (GP) with low-grade fever and 
generalized body aches. He was prescribed amoxicillin, 
paracetamol and multivitamins. Two days later he 
saw another GP after developing painful ulcerations 
in the mouth and lesions on his limbs and trunk. He 
was sent home with cefadroxil (a cephalosporin) and 
paracetamol. Despite taking the medications, his 
condition did not improve. He revisited the same GP 
the next day and was given oral prednisolone and 
cetirizine. Because his skin lesions were worsening, 
he sought treatment at the Accident and Emergency 
Unit (A & E) of UMMC on the third day after 
the first ulcerations appeared. At the A&E, the 
medical officer noted that he had large areas of 
hyperpigmented lesions with blisters and superficial 
erosions in some, involving the limbs and trunk 
along with erythematous superficial ulcerations on 
the hard palate. He had no previous allergies and 
noted that he had taken cefalexin (a cephalosporin) 
and amoxicillin in the past with no adverse reactions. 
He was then admitted to the Acute Medical Unit 
under the care of the Dermatologist. The case was 
reviewed and detailed history including previous 
drug history was taken. A diagnosis of Toxic Epidermal 
Necrolysis (TEN) secondary to amoxicillin and 
cefadroxil was made.
Because of the severity of the drug reaction 
involving almost 40% of the skin, he was given 
intravenous hydrocortisone followed by high dose 
oral prednisolone. Over the next seven days, the 
skin lesions improved and he was able to eat. For 
blisters on the body, he was given wet wraps with 
dilute solution of potassium permanganate solution 
(KMnO4). Subsequently when the lesions were 
drying up, topical steroid creams were applied. 
He was discharged on the tenth day with 40mg of 
prednisolone daily and advised on a tapering dose 
of the steroid within the next two weeks. From the 
history of his previous exposure to amoxicillin and 
cephalosporin, it could have been that he had his 
sensitising dose then. 
Case Report 2
A 48-year-old Indian lady with type 2 diabetes mellitus, 
below-knee amputation of the left leg and a right 
diabetic foot ulcer, was admitted with abdominal 
pain and distension, associated with nausea and 
breathlessness. She also had fever with poor urine 
output. An initial diagnosis of nephrotic syndrome 
and sepsis secondary to the right diabetic foot 
ulcer was made. Intravenous Unasyn (ampicillin and 
sulbactam) was given after blood cultures were taken. 
She was also given intravenous frusemide for the fluid 
retention.
On the fifth day of admission, she developed 
erythematous, target-like, blistering lesions on the 
dorsum of her right hand and on the antecubital 
fossa of her left arm (Figures 1a and 1b). These 
lesions appeared around the area of the branula site. 
The initial impression was that these lesions could have 
been caused by the extravasation of the antibiotics 
into the tissue around the branula. She gave no past 
history of adverse reactions to any medication. She 
was prescribed dilute potassium permanganate soaks 
to the areas of the blisters. One percent hydrocortisone 
cream was prescribed topically on the non blistered 
target lesions.
 Figure 1a: 48-year- old female with Bullous Erythema Multiforme
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Over the next two days, the lesions progressed, 
involving both limbs and the upper part of her 
trunk. She was then started on intravenous 
hydrocortisone. A diagnosis of bullous erythema 
multiforme secondary to ampicillin and sulbactam 
(Unasyn) was made.
Case Report 3
A 44-year-old Malay man, with a background history 
of nephritic syndrome secondary to focal segmental 
glomerulosclerosis, chronic renal disease and 
hypertension, was seen by a General Practitioner (GP) 
for fever, sore throat and itchiness of his eye. He was 
initially prescribed cefixime (a cephalosporin) and 
then a week later, was given amoxicillin clavulanate 
(Augmentin) and paracetamol. One day after taking 
amoxicillin clavulanate, he developed rashes around 
his neck. He however continued taking the medication. 
Three days later, the rashes became worse and the 
fever persisted. 
He presented to the A&E of UMMC on the third day after 
the rash appeared and was admitted with red eyes, 
mucosal erosions and multiple target lesions, some 
of which were confluent, over the trunk and limbs. He 
also developed difficulty and pain on swallowing. He 
suffers from seafood allergy but has no known previous 
allergies to drugs. 
He was admitted to the Acute Medical ward under 
the Dermatology unit. The next day, we requested a 
list of medications from his GP whom he had visited 
four times in the past one month, for various 
complaints. He was on a number of drugs namely 
colchicine, allopurinol, ibuprofen, meloxicam, 
simvastatin, cefuroxime and amoxicillin clavulanate.
As his renal profile was deranged and he had 
worsening of the renal functions, (urea=24.4mmol/l, 
creatinine=809µmol/l) an ultrasound scan of his 
kidneys was done which showed bilateral renal 
parenchymal disease. A diagnosis of toxic epidermal 
necrolysis possibly due to cefuroxime, allopurinol 
and or amoxicillin clavulanate was made. He 
was put on intravenous hydrocortisone and 
subsequently a tapering-down course of oral 
prednisolone. For the skin lesions, wet wraps 
with dilute potassium permanganate were done. 
The patient recovered fully and was discharged 
ten days later. He was advised on the medications 
that he should not take and was given a medic 
alert badge with allergies to cefuroxime, allopurinol 
and amoxicillin clavulanate.
Case Report 4
A 28-year-old man who sustained head injuries during 
a road traffic accident, was admitted to the UMMC 
Intensive Care Unit (ICU). During his one-month 
stay in ICU, he was started on several intravenous 
antibiotics at different intervals, amoxicillin clavulanate, 
piperacillin tazobactam (tazocin), polymyxin and 
ampicillin sulbactam (unasyn). He was later transferred 
to the Neurosurgical ward. There he developed 
a nosocomial infection. He was given intravenous 
amoxicillin clavulanate for three days. On the sixth 
day of hospital stay in the neurosurgical ward, he 
noticed an erythematous rash associated with pruritus 
starting at the neck and left antecubital fossa. He 
was also started on cetirizine and ponstan. His rash 
improved. 
Figure 1b: Same patient showing bullous eruptions on the dorsum of 
the hand
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After a week, he was discharged with amoxicillin 
clavulanate, and cetirizine. The rashes worsened 
after one day and started to spread to the upper and 
lower limbs, chest and abdomen. He was readmitted 
the next day with widespread painful maculopapular 
rash and joint pain. Blisters were present, especially 
on the trunk, palmar aspects of his hands, dorsum 
and sole of his feet (Figure 2a and 2b). He also had oral 
ulcers and areas of superficial erosions on his penis. 
He was referred to the Dermatology team, who 
saw the patient and a diagnosis of SJS secondary 
Figure 2a: A 28 –year-old male with SJS showing target lesions. Figure 2b: Same patient showing superficial blisters appearing on the 
trunk
Table 1: Summary of similarities between the four cases.
Case 1 Case 2 Case 3 Case 4
Known drug allergies Nil Nil Nil Nil
Common Drug  
Denominators seen:   
Amoxicillin,
Cefadroxil
Ampicillin 
Sulbactam
(Unasyn)
Cefuroxime, 
Amoxicillin 
clavulanate 
(Augmentin), 
Allopurinol
Amoxicillin 
clavulanate
(Augmentin)
Previous exposure to 
drugs: 
Treated with cefalexin 
and amoxicillin in the 
past.
No previous use of 
ampicillin sulbactam 
recorded.
Treated with 
cefuroxime, 
amoxicillin 
clavulanate and 
allopurinol in the past.
Treated with 
intravenous 
amoxicillin 
clavulanate on two 
occasions.
Re-challenged with  
current drugs.  
Shortened onset of  
symptoms.
2nd day of antibiotic 
use
5th day of antibiotic 
use
2nd day of antibiotic 
use
6th day of antibiotic 
use
Diagnosis: Toxic Epidermal 
Necrolysis (TEN)
Bullous Erythema 
Multiforme (BEM)
Toxic Epidermal 
Necrolysis (TEN)
Steven Johnson 
Syndrome (SJS)
Response to  
corticosteroids. 
Discharged after 10 
days of admission.
Rashes improved after 
12 days. Was not 
discharged as she had 
other comorbidities 
Discharged after 10 
days of admission.
Discharged after 7 
days of admission.
Table 1 summarises the similarities between the 4 cases seen. In 3 of the cases seen, sensitisation to the drug had occurred previously when the 
patients were exposed to the initial dose. The last case (case # 4) was sensitised during the admission to the UMMC for his head injury where he was 
given amoxicillin clavulanate.
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to amoxicillin clavulanate was made. He was 
started on oral prednisolone, dilute potassium 
permanganate topically to the areas of blisters and 
additional topical creams to the erythematous, non 
blister areas.
The patient recovered and was discharged one week 
later. 
In relation to the four cases above, the similarities are 
highlighted in Table 1.
Discussion
Epidemiological Data And Clinical
SJS and TEN are two related mucocutaneous reactions 
characterised by blistering lesions involving the 
epidermal region of the skin and erosions of the 
mucous membrane. The incidence are 1 to 6 and 
0.4 to 1.2 per million person-years respectively (1, 5).
The spectrum of cutaneous drug reactions range 
from the mild macular-papular erythematous rashes 
to fixed drug eruptions, erythema multiforme (EM), 
bullous erythema multiforme (BEM), Steven Johnson 
Syndrome (SJS) and the most severe which can lead to 
significant mortality, toxic epidermal necrolysis (TEN).
(Table 2).
Table 2: The spectrum of Adverse Cutaneous Drug Reactions 
Maculopapular rash MILD
Erythema Multiforme
Bullous Erythema Multiforme
Erythema Multiforme Major
Stevens-Johnson Syndrome
Toxic Epidermal Necrolysis  SEVERE
Table 2 summarises the spectrum of cutaneous drug reactions ranging 
from mild maculopapular rash to life-threatening TEN
 
The usual mild forms of cutaneous drug reactions 
include dusky erythema without blisters as in erythema 
multiforme, target lesions, where there is some degree 
of ischaemia to the superficial layer of the skin, to the 
most severe form involving separation of the epidermis 
from the dermis as in toxic epidermal necrolysis 
(TEN), whereby sheets of the epidermis separate out 
from the dermis. (Figure 3) This is the most severe, 
and in some cases, can be fatal if prompt treatment is 
not instituted (6).
SJS and TEN have a strong association with specific 
medication. In most studies, it has been shown that the 
rates of exposure to certain types of drugs are similar 
in SJS, SJS-TEN overlap and TEN (1, 5, 7, 8). Around 50% 
of SJS and more than 80% of TEN is caused by drugs 
(1, 9, 10). The list of drugs with the most significant 
association are shown in Table 3. The risk was found 
to be highest within a period of 4 to 28 days between 
the first initiation of the drug and onset of adverse 
reaction (10). Adverse drug reactions occur more 
frequently in recent times partly due to improper use 
of antibiotics, as can be seen in the cases highlighted 
above. Antibiotics are most commonly prescribed for Figure 3: TEN- Slide of another patient with a similar condition
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Table 3: Medications associated with high risk of SJS or TEN10
Antibiotics:
•Cotrimoxazole 
•Anti-infective sulfonamides
Sulfasalazine
Allopurinol
Anti-inflammatory drugs:
•Sulfasalazine
•Oxicam-NSAIDs
Antiepileptic drugs:
•Lamotrigine
•Carbamezapine
•Phenytoin
•Phenobarbital
Antiretroviral:
•Nevirapine
Table 3 summarises the list of drugs that are regularly associated with 
causing SJS or TEN.
 
upper respiratory tract infections, as is the case of three 
of the cases above (11). Other risk factors include HIV 
infection, cancer and collagen vascular disease (7). The 
high risk reflects frequent drug use in comparison to 
the general public.
The immune system is thought to play a role in most 
adverse drug reactions including those which involve 
the skin (12). There have been many papers that 
postulate an immunological reaction to drugs as the 
cause of SJS and TEN (1, 12). This is further strengthened 
by the fact that SJS and TEN can recur within 48 
hours of a rechallenge, in comparison to an average 
of 14 days after initial reaction (1). This is because it 
takes around two weeks of continuous treatment for 
sufficient antibodies to develop and cause a reaction. 
Some drugs, like antibiotics, are used for five to seven 
days and therefore the antibodies produced are not 
adequate to cause a reaction. However, when the 
offending drug is unknowingly re-introduced to the 
patient, this would cause a sensitisation effect as can 
be seen in the cases above, mounting a severe reaction 
within a short period of time. 
The hapten hypothesis has been used to explain the 
immunological mechanism of SJS and TEN (12). Not 
only is the skin equipped with an active immunological 
defence system, it is also able to metabolise drugs. 
The hypothesis proposes that drugs or the reactive 
metabolites of the drugs, act as haptens which bind 
covalently to endogenous proteins (which in this 
case would be the epidermal proteins) forming a 
compound that would trigger the immune system 
(12). The epidermis is then infiltrated with activated 
lymphocytes, mostly CD8 cells and macrophages (1, 
12)
With the two disorders, sepsis is the major cause 
of death. Visceral involvement, increased urea and 
creatinine and extensive epidermal detachment 
indicate poor prognosis (1). However, prognosis is not 
affected by HIV infection or the type and dosage of 
drug used. 
Histopathology
SJS and TEN are shown to be similar in terms of 
histopathological findings. Very severe cases of 
SJS may include large areas of patchy epidermal 
necrolysis with bullae and target lesions; while in 
TEN there would be large areas of the body with 
sheets of epidermis separating from the dermis. 
The difference noted between the two are the extent 
of epidermal detachment, which is more pronounced 
(>30%) in TEN causing a higher mortality rate (7). Cases 
that involve epidermal detachment between 10 to 30% 
are considered an overlap of the two syndromes (1, 6, 
7 ).
In most cases, a skin biopsy is not necessary as it does 
not help in determining the cause, whether it is drug-
induced or not. A diagnosis of adverse cutaneous 
drug reaction, either SJS or TEN, can be made with a 
careful and detailed history as well as an accurate 
account and confirmation of the previous medications 
taken and the time sequence of the occurrence of 
the typical lesions, usually gives an accurate clinical 
impression. This is further enhanced by finding 
the typical lesions on the skin (target lesions, with 
or without intraepidermal blisters, and a positive 
Nikolsky sign, and or superficial erosions on the 
mucous membranes). A re-challenge with the 
likely causative drug, although NOT usually done 
because of the possible severe reaction which can be 
life-threatening, may confirm the definite drug causing 
the reaction. However, this is not advisable because 
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it is unethical to subject a patient to a possibly life-
threatening test. 
Management
Adverse cutaneous drug reactions, if severe, like SJS and 
TEN, should be recognized as an acute dermatologic 
emergency and therefore, should be managed on 
the wards. Depending on the severity and the extent 
of the skin involvement, it may be necessary to have 
the patient monitored in the intensive care unit or the 
burns unit.
The management is similar to that of a patient 
with thermal burns which includes aggressive fluid 
replacement, nutritional support special attention 
given to ensure that the patient gets a high 
protein diet; if there is sepsis, careful choice of 
antibiotics is absolutely essential, to prevent more 
reactions; aseptic handling and avoidance of adhesive 
material and proper skin care with open dressings 
and the use of dilute potassium permanganate wet 
wraps will assist in the prevention of superficial 
infection and allows the healing process to occur. 
Hence, optimal nursing care is vital to ensure a smooth 
and rapid recovery. Also all potentially responsible 
medication should be withdrawn immediately. 
All drugs, especially those introduced within a 
month of the reaction should be considered suspect 
(1).
Most therapies by administering corticosteroids or 
other disease-modifying therapies have yet to be 
proven for their effectiveness by controlled studies. 
There has been much debate on whether corticosteroids 
should be used in the treatment of SJS and TEN (1, 6, 
13). Therapeutic use of systemic corticosteroids have 
been advocated in some studies (6) and have been 
found inconclusive in others (13). Although toxic 
epidermal necrolysis can develop in patients receiving 
high-dose corticosteroid therapy (10), recent studies 
have not found a direct causal effect (14). Others 
like plasmapheresis and immunoglobulin therapy 
have been attempted but their effectiveness remain 
doubtful. Most papers suggest aggressive supportive 
treatment should be the main priority instead. From 
our experience, as can be seen in all four cases above, 
the use of corticosteroids is beneficial in improving 
and reducing further advancement of skin lesions.
Conclusion
The diagnosis and management of SJS and TEN are 
complex and controversial. As these conditions are 
associated with devastating sequelae, more effort 
should be made to clarify the classification of clinical 
features of this disorder. It is important for physicians 
to promptly recognize the signs and symptoms as 
only early intervention is best at this point in time. 
Drug-induced reactions should always be part of the 
differential diagnosis for any adverse reaction. Even if a 
certain drug borders on ‘probable’ that drug should be 
withdrawn. At UMMC, any allergic or adverse reaction 
to a drug is notified to the Malaysian Adverse Drug 
Reactions Advisory Committee (MADRAC) via a written 
form. After recovery, patients should be advised 
to subscribe to MedicAlert, to obtain some form of 
identification in order to prevent future occurences; 
and avoid the drug and all its chemically-related 
compounds. 
A multidisciplinary approach is required to manage 
these two conditions. Regular and consistent 
input is needed from the dermatologists and the 
plastic surgeons to reduce progression of the 
skin lesions. The nursing staff plays a vital role in 
ensuring that the proper skin care and dressings 
are carried out. Nutritionists are also involved as a 
high-protein diet is known to speed up the healing 
process.
In Malaysia, where the practice of “doctor shopping” 
is common, it is essential that patient education 
be emphasised as an important part of patient 
management. This should be taken up by medical 
schools to ensure that this component is part of their 
undergraduate curriculum.
With the increasing awareness of health care 
professionals and improved reporting, it is predicted 
that the frequency and number of patients with adverse 
drug reactions may be on the increase; more so when 
antibiotics are used indiscriminately. Over-prescribing 
antibiotics can also lead to antibiotic resistance, 
resulting in ineffective treatment of infections. In fact, 
the World Health Organization identified this issue as 
one of the threats to global public health security and 
suggested the urgent need to promote judicious and 
rational antibiotic prescribing practices (15). The cases 
above could have been avoided had there been careful 
oriGiNal artiCle  JuMMeC 2010: 13(1)
57
use of medication, especially antibiotics. Clinicians 
should not succumb to the pressure of prescribing 
antibiotics just to please their patients. Antibiotics 
should be prescribed only if they are proven to be 
beneficial to the patient. 
Although the likelihood of a severe reaction is very slim, 
less than 1 reaction per 5000 exposed patients, they 
are mostly undetected in premarketing clinical trials 
(1). Therefore it is the clinician’s responsibility to detect 
and report these reactions to the regulatory bodies, 
when they do occur. In Malaysia, all drug-induced 
reactions should be reported to the Malaysian Adverse 
Drug Reactions Advisory Committee (MADRAC). The 
report can be made by filling up blue cards which are 
available at the hospital or submitted via the Internet 
at their website (16).
The current practice of prescribing and dispensing 
of medicines done at private clinics and dispensaries 
should be reviewed. With the increasing numbers 
of adverse cutaneous drug reactions seen recently 
, the authors suggest that prescribing of drugs 
should be done judiciously and with adequate 
patient education. Patient should also be given 
information of the effects and possible side effects of 
the drugs prescribed. This should be re-emphasised 
when the drugs are dispensed by the pharmacists. 
The authors believe that the prevalence of adverse 
drug reactions, may, to some extent be reduced if 
there is a separation between prescribing and 
dispensing of the drugs as is practiced in hospitals in 
this country.
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Introduction
A 76-year-old gentleman was referred with a history 
of progressively worsening ulcer on the left side of his 
scrotum of 6 months duration. He denied any history 
of trauma to the scrotum and there was no exposure to 
industrial irritants noted.
Examination revealed a fungating ulcer with everted 
edges mainly at the left side of scrotum encroaching 
slightly the base of the penis and to the right side of 
the median raphe. There was also bilateral fixed and 
matted inguinal lymphadenopathy.
His laboratory tests were within normal limits. Wedge 
biopsy of the lesion showed a moderately differentiated 
SCC. A computed tomography (CT) imaging scan and a 
Magnetic Resonance Imaging (MRI) for staging revealed 
a well localized lesion in the scrotum with bilateral 
inguinal lymphadenopathy and with no evidence of 
other distant metastasis (Figure 1).
The patient was subjected to a wide local excision 
of the tumour with scrotal skin flap reconstruction. 
Histopathology revealed a well-differentiated SCC with 
no lymphovascular permeation and surgical margins 
were noted to be free of tumour. He then underwent 
and completed three cycles of chemotherapy with 
carboplatin and 5-Fluorouracil (5-FU) regime in view of 
the matted bilateral inguinal lymphadenopathy. Post 
Chemotherapy, he underwent bilateral radical inguinal 
lymphadenectomy for the persistent lymphadenopathy 
and the histopathology confirmed no spread to the 
lymph nodes (10 and 28 lymph nodes on the right and 
left respectively) except for the skin nodule overlying 
the left nodes.
This gentleman has not presented with any evidence of 
recurrence or metastasis in the last two years of follow-
up, both clinically and on imaging.
Discussion
Malignant tumour of the scrotum is a very rare condition 
worldwide. The SCC of the scrotum is the commonest 
of the various neoplasm of the scrotum like Basal Cell 
Carcinoma, Malignant Melanoma and Paget’s disease 
(3). The incidence of this disease is only about 0.2 to 0.3 
cases per 100,000 men above the age of 35 years (4). 
Age of patients presenting with SCC of scrotum usually 
ranges from 50 to 60 years old (5). 
As in most cutaneous lesions, they usually seek medical 
advice about 12 months after the onset of the ulcer 
because of extensive usage of topical treatment (6). 
This delay could lead to a more advanced stage at the 
time of diagnosis.
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Ipsilateral inguinal lymphadenopathy is usually 
noted in about 40% to 50% of patients and only half 
of them i.e 25% have proven metastasis to the lymph 
nodes (6).
Staging of the disease can be done with CT scan, 
although it is not a reliable modality to differentiate 
between inflammatory and metastatic lymph nodes 
(3). MRI is rapidly emerging as a reliable tool for this 
purpose (7). Currently used staging system for SCC of 
the scrotum is shown in Table 1.
Figure 1: Staging system for Scrotal Carcinoma (6)
stage description
A1 Localised to scrotal wall
A2 Locally extensive tumour invading adjacent 
structures (testis, spermatic cord, penis, pubis, 
perineum)
B Metastaticdisease involving inguinal luph nodes 
only
C Metastatic disease involving pelvic lymph nodes 
without evidence of distant spread
D Metastatic disease beyond the pelvic lymph 
nodes involving distant organs
Upon confirmation of the diagnosis by biopsy of the 
scrotal lesion, the treatment of choice is a wide local 
excision with a margin of 2 cm and the defect is closed 
primarily or with split-thickness skin grafting if necessary 
(3). Lymph node management is controversial—
unilateral versus bilateral lymphadenectomy and the 
timing of lymphadenectomy (prophylactic versus 
delayed). The need for radical inguinal lymph node 
dissection is debatable as only 25% of cases show 
evidence of metastasis as compared to the morbidity 
of the procedure. Therefore, it is recommended 
that lymph node dissection be undertaken in 
cases with proven metastasis i.e Sentinel node biopsy 
positive (3). Sentinel biopsy as described by Cabanas 
in 1977 (8) for penile cancer is no more recommended 
due to high false negative rates (25%, range 9-50%) 
(9). Similarly, we feel that sentinel biopsy for scrotal 
squamous cell carcinoma should not be done and 
a better alternative would be a modified radical 
inguinal lymphadenectomy. Our patient was noted 
to present with bilateral fixed and matted inguinal 
lymphadenopathy which would have complicated 
any attempt of an inguinal lymph node dissection. 
Therefore, a course of chemotherapy was given. 
Clinical improvement of the lymph node status was 
noted but in view of the persistence, it was then 
decided that the patient should undergo a left radical 
Figure 1: CT scan showing enlarged Bilateral Inguinal lymph nodes
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lymphadenectomy plus a right modified inguinal 
lymphadenectomy. To the patient’s advantage, 
it was found in the histopathology that the 
lymph nodes had no evidence of metastasis and 
the operation itself was less morbid. Therefore, 
we propose the following algorithm (Figure 2) be 
used in the management of biopsy proven SCC of 
scrotum.
Radiation therapy is not effective in this condition 
and is reserved only for those with incomplete 
surgical resection and in patients who are unfit 
to undergo surgery (10). Chemotherapy has been 
reported to be quite successful in preventing the 
spread and recurrence of the disease. Reports 
showed good success in a couple of patients using 
bleomycin. However, these patients had low grade 
disease (11). Combination therapy of methotrexate, 
bleomycin and cisplatin achieved a 72% response 
rate in patients who had inoperable or metastatic 
squamous cell carcinoma of the male genital 
tract (12). Successful treatment was also reported by 
Hussein et al and Fisher et al by using a combination 
of Cisplatin and 5 Fluorouracil (13 & 14). Although, 
the number of patients was small i.e 29, those treated 
with neo-adjuvant Cisplatin and 5-Fluorouracil for 
fixed or recurrent nodal disease for penile cancer 
showed good response (66%) and in 38% of them, 
resection could be performed (14). Carboplatin 
was used in our patient because of the possible 
toxicity of Cisplatin in geriatric patients. Randomized 
multicenter trials are needed to determine the role 
of chemotherapy in the management of scrotal 
SCC.
Figure 2: Algorithm for management for biospy proven SCC 
FS – Frozen section; LN – Lymph node
Biospy proven SCC Scrotum
Non-palpable LN Fixed/MattedLNPalpable LN
Surveillance ChemotherapyModified LN dissection
Modified LN dissection ** Radical LN dissectionFS negative FS positive
** On ipsilateral side for poor grade  
   primary lesion
Surveillance Radical LN 
dissection
Adjuvant 
Chemotherapy *
* If at least two positive 
LN or extra-capsular nodal 
involvement
Wide Local Excision
OR
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Prognosis of this condition is poor with many series 
reporting death within 2 years of diagnosis; however, 
the prognosis is related to the stage of the disease 
as reported by Ray and Whitmore (6). Stage A1 has 
a survival rate of more than 75%, Stage B only 44%, 
whereas, Stage C & D has very minimal chance of 
survival (3 & 15).
Conclusion
SCC of the scrotum is a rare but aggressive condition. 
The best prognosis for this disease is achievable 
if diagnosed in early stage where a wide local 
excision with or without radical inguinal lymph node 
dissection and adjuvant chemotherapy could be 
administered. 
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Case Report
An ethnic Chinese male welder aged 32 initially 
presented to an orthopaedic surgeon complaining of 
gradually worsening low back pain associated with 
weakness of his lower limbs after a fall at home eight 
months earlier. Magnetic Resonance Imaging (MRI) of 
the lumbar spine showed a prolapsed intervertebral 
disc at the L5/S1 level. He, subsequently, underwent 
a discectomy. Post-operatively, MRI of the spine was 
reported as normal, however, his symptoms persisted 
and in fact worsened with pain involving his upper 
limbs especially the right elbow. The generalized 
musculoskeletal pain and weakness limited his 
movement. He complained of difficulty rising from his 
chair. He required a walking aid, became housebound 
and was unable to work. 
He lived with his parents and there was no family history 
of malignancy, bone disease or fractures. He had no 
dietary restrictions. He smoked about five cigarettes 
and consumed alcohol, three cans of beer daily.
He consulted a neurologist a year after his spine 
operation. Lumbar puncture and cerebrospinal 
fluid examination, nerve conduction studies, 
electromyogram and somatosensory evoked potentials 
were normal. MRI imaging of the brain, cervical and 
lumbar spine showed no significant abnormality. He 
was then referred to a rheumatologist and given a trial 
of corticosteroids empirically, dexamethasone 4mg 
TDS for 1 week for suspected connective tissue disease 
but did not improve.
Skeletal survey radiographs showed multiple lytic 
bony lesions proximally and distally in the long bones 
of all four limbs with some pathological fractures 
more marked over the right proximal radius (Figure 
1). 99m Technitium-methylene diphosphonate bone 
scintigraphy showed multiple symmetrical foci of 
increased uptake in the articular surfaces of his 
shoulders, hips, knees, several ribs bilaterally and 
the right elbow joint, consistent in hindsight with 
Looser’s zones/fractures (Figure 2). (26) Computerized 
tomogram (CT) of the neck, thorax, abdomen and 
pelvis was normal. 
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Figure 1: 99m Technitium-methylene diphosphonate bone scintigraphy 
(anterior view) shows multiple abnormal foci of increased uptake. (Dark 
areas)
 
 
 
Figure 2: Radiograph of the right radius and ulna shows a lytic lesion 
at the proximal radius with a healing pathological fracture. (Arrow) 
 
Subsequently, he was referred to an orthopaedic 
oncologist with the presumptive diagnosis of primary or 
metastatic bone malignancy. Core needle bone biopsy 
of the right radius showed features suggestive of osteo-
fibrous dysplasia or reactive bone formation. Diagnosis 
of myeloma or other haematological malignancy was 
excluded after appropriate investigations. Review of his 
biochemistry at this stage prompted an endocrinology 
consult to exclude metabolic bone disease.
Physical examination revealed an alert, well-nourished 
man who was unable to walk unaided. His weight was 
94kg and height was 160cm with no obvious skeletal 
deformity. He had gained 10kg due to immobility 
attributed to his illness. There was no muscle wasting. 
Grading of power was difficult as movement was limited 
by musculoskeletal pain in all four limbs. Proximal 
myopathy was evident; power was 4/5 at the hips and 
shoulders and 5/5 distally. Passive movement of his 
limbs and palpation of his ribs also caused pain. He 
had no sensory deficit and was not incontinent. Knee, 
ankle, biceps, triceps and supinator reflexes were brisk 
bilaterally. Central nervous, cardiovascular, respiratory 
and abdominal systems examination was normal. 
Full blood count, erythrocyte sedimentation rate, 
renal, liver and thyroid hormone profile as well as 
plasma protein electrophoresis urinanalysis and urine 
for Bence-Jones protein were normal. Serum alkaline 
phosphatase (ALP) was elevated 302 IU/l (25-100 
IU/L), calcium 2.31 µmol/l (2.2-2.6 µmol/L), albumin 36 
g/L (35-50 g/L), phosphate was low 0.5 mmol/L (0.8-
1.5 mmol/L), intact parathyroid hormone (iPTH) 7.4 
pmol/L (1.1-7.3 pmol/L), 24 hour urinary phosphate 
was inappropriately normal 16.7 mmol/24H (15-50 
mmol/24H)- indicating urinary phosphate wasting in 
the presence of hypophosphataemia, 24 hour urinary 
calcium excretion 3 mmol/24H (2.2-7.5 mmol/24H) and 
25-hydroxyvitamin-D low 35 mmol/L (60-160 mmol/L). 
Serum 1, 25-dihydroxyvitamin D was not assayed. 
He was diagnosed to have hypophosphataemic 
osteomalacia, most likely due to oncogenic 
osteomalacia (OOM). He was commenced on oral 
neutral phosphate solution 45 mls TID, calcitriol (1,25- 
dihydroxycholecalciferol) 0.25 µg BID and calcium 
carbonate 1 g BID. Despite treatment, his serum 
phosphate remained low and symptoms unchanged. 
His compliance to this regime was questionable. 
A search for the primary tumour was initiated. First, 
he was referred to an otorhinolaryngologist and 
endoscopic examination revealed a small (0.5 x 0.5 cm) 
soft tissue nasopharyngeal mass which was surgically 
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removed but this did not lead to biochemical or clinical 
improvement. Histopathology showed fragments of 
seromucinous glands and lymphoid tissue partially 
covered by respiratory-type epithelium and stratified 
squamous epithelium. 
Positron Emission/Computerized Tomogram using 
17.3 mCi (640 MBq) fluorodeoxy-D-glucose (PET/CT-
F-18-FDG) was performed which revealed an area of 
increased uptake and a corresponding lesion at the 
superior posterior aspect of the right arm. (Figures 
3 and 4) Clinical examination revealed a small firm 
mass. It was surgically removed resulting in prompt 
normalization of his biochemical parameters. 
Macroscopically a 3 cm x 1.5 cm x 1.5 cm mass of 
fibrofatty tissue was excised. Microscopy revealed a 
lesion consisting of plump proliferating fibroblasts 
showing mild cellular pleomorphism and mitosis with 
scattered multinucleated giant cells. An area of osteoid 
formation continuing into an area of lamellar bone was 
also noted. 
Discussion 
McCance described a patient in 1947 whose vitamin 
D-resistant osteomalacia was cured by resection 
of a benign osteoid tumour of the femur (1). OOM 
is characterized by the biochemical profile of low 
serum phosphate, normal calcium, elevated ALP, 
low plasma 1, 25-dihydroxyvitamin-D, increased or 
inappropriate 24 hour urinary excretion of phosphate 
 
 
Figure 3: PET F-18-FDG coronal image shows abnormal increased 
uptake at the superior posterior aspect of the right arm. (Arrow) 
 
 
 
 
Figure 4: Corresponding CT image shows a lesion at the superior posterior aspect of the right arm. (Arrow)
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and osteomalacia (2). Serum iPTH is usually normal 
or mildly elevated (3). Our patient had biochemical 
features consistent with the diagnosis. Differential 
diagnoses of hypophosphataemic osteomalacia are 
shown (Table 1).
Common causes of osteomalacia include phosphate 
depletion and disorders of vitamin D metabolism. 
Elevated ALP is a nonspecific finding consistent 
with bone fracture from any cause. It does rule 
out hypophosphatasia, a rare heritable cause of 
osteomalacia, which presents in adulthood with 
recurrent metatarsal stress fractures or symptomatic 
chondrocalcinosis. Hypophosphataemia, caused by 
renal phosphate wasting is normally a potent stimulator 
of 1, 25-dihydroxyvitamin D production. Low levels of 
1, 25-dihydroxyvitamin D however is not diagnostic of 
oncogenic osteomalacia. Low 1, 25-dihydroxyvitamin 
D levels combined with severe hypophosphataemia 
suggest rare disorders that cause both renal phosphate 
wasting and down regulation of 25-hydroxyvitamin 
D-1-α-hydroxylase resulting in osteomalacia. An 
inherited cause is unlikely in our patient given no family 
history of metabolic bone disease and advanced age at 
presentation, suggesting an acquired disorder is more 
likely (4, 5). Fanconi’s syndrome, or renal phosphate 
wasting associated with glycosuria, aminoaciduria, 
hyperuricosuria and type-2 renal tubular acidosis is 
usually inherited but may be acquired. Causes include 
myeloma, Sjogren’s syndrome or heavy metal exposure. 
Uric acid and bicarbonate were normal. Urinalysis did 
not show glycosuria. Low 25-hydroxyvitamin D is not 
a feature of OOM. We hypothesize that the low levels 
seen in this patient may have been the result of long 
term lack of sun exposure due to immobility.
Patients with OOM as in this case typically have muscular 
weakness and bone pain that progresses gradually over 
months to years and can resemble a systemic disease or 
neuromuscular disorder resulting in diagnostic delay. 
OOM should be considered if radiographs demonstrate 
Looser’s zones and malnutrition as a cause of 
osteomalacia has been excluded. There should be no 
gastrointestinal or genitourinary problem to account 
for the abnormal biochemical profile (6-8).
The primary tumour is usually of mesenchymal origin 
with prominent fibrous and vascular characteristics. 
Hemangiopericytoma, benign angiofibroma, giant cell 
tumours of bone and soft tissue, tumours associated 
with multiple myeloma, chronic lymphocytic leukemia, 
fibrous dysplasia of bone and neurofibromatosis 
have been described to cause OOM (2, 7-10). The 
tumor is often small, benign and slow growing; 
usually located over the extremities, head and neck. 
50% of the tumours are located in the skeleton and not 
easily detectable on physical examination or routine 
radiography accounting for delay in diagnosis (3, 
11-13).
Dual-energy x-ray absorptiometry may show low bone 
density, consequence of decreased mineralization of 
bone due to osteomalacia, not osteoporosis (4). T2-
weighted short-tau inversion-recovery (STIR) MRI,201 
thallium and whole body 99m technetium sestamibi 
scintigraphy have been recommended for tumour 
search, as well as 111 indium pentetreotide or octreotide 
scintigraphy (7, 8, 11, 14, 15). Tumours frequently 
express somatostatin receptor subtype-2 and bind 
111 indium labelled octreotide. Not all mesenchymal 
tumours causing OOM are positively identified by this 
Table 1: Causes of hypophosphataemic osteomalacia
Inherited causes Acquired causes
X-linked hypophosphataemic rickets
(associated with loss of function of PHEX) Oncogenic osteomalacia 
Autosomal dominant hypophosphataemic rickets
(mutation of FGF-23 gene)
Vitamin D deficiency
Autosomal recessive hypophosphataemic rickets 
(mutation of dentin matrix protein)
Fanconi's syndrome
Aluminum ingestion (reduces gastrointestinal  
absorption of phosphate)
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method (17). We did not have this facility. Successful 
tumour localization using PET/CT-F-18-FDG when 
multiple other imaging tests have failed has been 
described with increasing frequency (16).
The tumour produces fibroblast growth factor 23 (FGF-
23), phosphatonin or phosphaturic hormone which 
underlies all the metabolic abnormality associated with 
hypophosphataemic syndrome. FGF-23 inhibits renal 
phosphate transport and 1, 25-dihydroxyvitamin D 
production (17-21). The injection of FGF-23 transfected 
cells into mice results in the characteristic features of 
OOM (3). However FGF-23 level is also increased in 
patients with X-linked hypophosphataemic rickets 
by the loss of function of the phosphate regulating 
gene with homologies to endopeptidase on the X 
chromosome (PHEX). It is speculated that PHEX protein 
functions as a protease to cleave FGF-23 and inactivate 
its function (3, 22, 23). Some other factors such as 
matrix extracellular phosphoglycoprotein and secreted 
frizzled-related protein 4 have also been implicated in 
the pathogenesis of OOM. Successful selective venous 
sampling for FGF-23 with MRI to localize tumours has 
been described (13, 16).
The clinical course of OOM is dramatically affected 
by removal of the causative tumour, resulting in 
rapid resolution of biochemical abnormalities. There 
is gradual improvement of bone mineralization 
and symptoms (2, 8, 10). Phosphate 1-4 grams/
day in divided doses and 1, 25-dihydroxyvitamin 
D replacement is recommended but with limited 
success (3, 8). Long term complications of treatment 
include secondary hyperparathyroidism and ectopic 
calcification, including nephrocalcinosis (24). As short 
term treatment, octreotide has been shown to rapidly 
correct serum phosphate levels and ALP activity in 
patients with tumours that were detected by octreotide 
scintigraphy (25). Others report failure to normalize 
serum phosphate but successful suppression of serum 
FGF-23 with octreotide therapy (26). CT guided radio 
frequency tumour ablation has been described; it may 
offer an effective, less invasive alternative to classical 
surgery especially for inaccessible tumours (27).
Conclusion
Diagnosis of OOM requires recognition of the typical 
clinical, biochemical and radiological features. Other 
conditions associated with hypophosphataemia must 
be excluded. Follow up with surveillance for tumour 
recurrence and biochemical monitoring is warranted. 
Our patient presented with the typical features of 
OOM and followed the classical route; with delay in 
obtaining the final diagnosis and difficulty locating the 
primary causative tumour. Fortunately, he responded 
promptly with normalization of phosphate and alkaline 
phosphatase accompanied by resolution of pain after 
tumour resection. 
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